Heart failure involving the RIGHT VENTRICLE.
| Excerpt | Reference |
|---|
| "Even though congestive heart failure is extremely common, the mechanisms responsible for the clinical manifestations remain a puzzle." | ( Burch, GE, 1978) |
| "Thus, in CMH, congestive heart failure is attended by increased plasma renin activity without a significant increase in aldosterone production, a dissociation which does not appear to be due to adrenal unresponsiveness to angiotensin II or to potassium depletion." | ( Galla, JH; Hayslett, JP; Kotchen, TA; Schneider, G, 1977) |
| "Congestive heart failure is a syndrome common in the United States, especially in elderly patients." | ( Parmley, WW, 1992) |
| "Congestive heart failure is the most common cause of death in young adults with thalassaemia major." | ( Bellone, P; Derchi, G; Forni, GL; Jappelli, S; Lupi, G; Randazzo, M; Vecchio, C; Zino, V, 1992) |
| "Because cardiac failure is marked by a loss of vagal tone, we hypothesized that adenosine injection in dogs with failing hearts would reduce heart rate." | ( Belloni, FL; Hintze, TH; Wang, J, 1992) |
| "Congestive heart failure is a condition associated with increased plasma norepinephrine levels." | ( D'Onofrio, F; De Riu, S; Marrazzo, G; Paolisso, G; Varricchio, M; Verza, M, 1991) |
| "Cardiac failure is the principal medium-term complication of myocardial infarction." | ( Cohen-Solal, A; Gourgon, R; Guéret, P; Himbert, D, 1991) |
| "Severe congestive heart failure is a fatal illness." | ( Yancy, CW, 1991) |
| "These forms of cardiac failure are often subject to diagnostic error." | ( Aumont, MC; Badaoui, G; Dahan, M; Paillole, C; Taboulet, P, 1990) |
| "Congestive heart failure is characterized by excessive neuro-humoral excitation as evidenced by direct recordings of sympathetic activity and by increased plasma levels of catecholamines, renin, angiotensin II and arginine vasopressin." | ( Shepherd, JT, 1990) |
| "Acute cardiac failure is a symptom of a defined heart disease." | ( Teichmann, W, 1990) |
| "Congestive heart failure is characterized by both disturbances in electrolyte homeostasis and neuro-hormonal regulation." | ( Francis, GS, 1990) |
| "Congestive cardiac failure is a syndrome in which a decrease of cardiac output triggers a series of neuro-humoral compensatory mechanisms in part involving the kidney." | ( Gross, P; Hensen, J; Ketteler, M; Schömig, A; Wichmann, A, 1989) |
| "Congestive heart failure is a complex clinical syndrome characterized by circulatory and metabolic abnormalities." | ( Francis, GS, 1989) |
| "1." | ( Parmley, WW, 1989) |
| "Congestive heart failure is a common clinical syndrome, with a relatively poor prognosis in its advanced stages." | ( Parmley, WW, 1989) |
| "Congestive heart failure is the most arrhythmogenic disorder in cardiovascular medicine." | ( Gottlieb, SS; Kessler, PD; Packer, M, 1986) |
| "Congestive heart failure is a complex clinical syndrome characterized by striking abnormalities of the autonomic nervous system." | ( Cohn, JN; Francis, GS, 1986) |
| "Congestive heart failure is an especially disabling consequence in up to 49% of the age-class 75 to 80 years." | ( Bertel, O; Marx, B; Nägeli, B, 1989) |
| "Myocardial failure is clinically silent, most often progresses slowly, and is documented by a depressed left ventricular ejection fraction." | ( Factor, S; Le Jemtel, TH; Mancini, DM; Sonnenblick, EH, 1986) |
| "Cardiac failure is characterised by a marked reduction in renal blood flow." | ( Richards, AM; Robertson, JI, 1988) |
| "Congestive heart failure is characterized by increased circulating levels of ANF; however, there appears to be an attenuation in the renal response to the hormone." | ( Burnett, JC; Edwards, BS; Zimmerman, RS, 1987) |
| "Congestive heart failure is an unusual complication of the hyperreninemia of Wilms' tumors." | ( Goertz, KK; Lowman, JT; Poisner, AM; Stine, KC, 1986) |
| "Congestive heart failure is a clinical syndrome with inadequate cardiac output and increased venous pressure, characterized by hyperfunction of the sympatho-neuro-endocrine system, favoring maximal vasoconstriction in non-essential organs and retention of salt and water." | ( Rutishauser, W, 1986) |
| "Congestive heart failure is a complex physiopathological state where both myocardial hypo-contraction and excessive peripheral vasoconstriction lead to lower cardiac output." | ( Hannedouche, T; Saoudi, N, 1987) |
| "Congestive heart failure is associated with hypoperfusion to various organs including the sites of drug clearance, i." | ( Dickstein, K; Shammas, FV, 1988) |
| "Congestive heart failure is a serious health-care problem that is associated with a high mortality." | ( DiBianco, R, 1988) |
| "Many studies of congestive heart failure are done without explicit diagnostic criteria." | ( Alderman, MH; Marantz, PR; Tobin, JN, 1988) |
| "Usually congestive heart failure is considered to develop as a vicious cycle in which impaired cardiac output, increased peripheral resistance, decreased renal blood flow, increased renin release and further increased peripheral resistance and decreased cardiac output are important constituents." | ( Wennmalm, A, 1986) |
| "Congestive heart failure is characterized by peripheral circulatory abnormalities including arterial and venous vasoconstriction and redistribution of regional blood flow." | ( Fournier, JF; Hannedouche, T, 1987) |
| "Congestive heart failure is accompanied by a number of compensatory mechanisms that may overshoot the mark." | ( Parmley, WW, 1985) |
| "Chronic congestive heart failure is a frequently occurring disease associated with an impaired quality of life and significant mortality rate." | ( Applefeld, MM, 1986) |
| "Chronic congestive heart failure is a state with reduced digoxin clearance by the kidney, which could lead to digoxin intoxication not explicable by overdose, reduced renal function or the effect of interacting drugs." | ( Koorevaar, G; Naafs, MA; Schopman, W; Silberbusch, J; van der Hoek, C; van Duin, S, 1985) |
| "The incidence of congestive heart failure is increasing in the United States." | ( Cohn, JN; Francis, GS; Goldsmith, SR; Levine, TB; Olivari, MT, 1984) |
| "Congestive heart failure is frequently associated with elevated systemic vascular resistance." | ( Sullivan, JM, 1983) |
| "Signs of congestive heart failure are absent." | ( Ebrecht, G; Jacob, R; Jörg, E; Kissling, G; Rupp, H; Takeda, N, 1984) |
| "The development of cardiac failure is accompanied by a more stable rise of plasma cAMP." | ( Baltiĭskaia, NV; Korochkin, IM, 1982) |
| "Cardiac failure is usually defined according to clinical and haemodynamic criteria at rest although these patients are mainly symptomatic on effort." | ( Aubran, M; Camous, JP; Gibelin, P; Morand, P; Rainart, JP, 1984) |
| "Congestive heart failure is a serious pathological heart state which is manifested by cardiorespiratory signs and symptoms." | ( Duncklee, JE, 1984) |
| "Congestive heart failure is usually accompanied by cardiovascular signs of an increased sympathetic and a decreased parasympathetic efferent activity." | ( Malliani, A; Pagani, M, 1983) |
| "Cardiac failure is produced by massive quantities of isoproterenol, and the degree of cardiac failure is dose dependent." | ( Iams, SG; Yeager, JC, 1981) |
| "Congestive heart failure is the end product of a progressive series of events resulting from acute myocardial damage." | ( Dzau, VJ; Gibbons, GH; Pratt, R, 1994) |
| "Congestive heart failure is a debilitating disease characterized by impaired cardiac function with accompanying activation of a variety of neural and hormonal counter-regulatory systems." | ( Cox, HS; Esler, MD; Jennings, GL; Kaye, DM; Lambert, GW; Lefkovits, J; Turner, AG, 1995) |
| "Since congestive heart failure is characterized by abnormal intracellular Ca2+ homeostasis, we sought to delineate MRPES behavior before and after the production of heart failure to obtain insights into the relation between altered mechanical performance and Ca2+ handling." | ( Freeman, GL; Prabhu, SD, 1995) |
| "Congestive heart failure is characterized by a clear-cut impairment of arterial compliance of medium-sized arteries, but whether this alteration is irreversible or can be favorably affected by cardiovascular drugs currently used in congestive heart failure treatment is unknown." | ( Carugo, S; Failla, M; Giannattasio, C; Grassi, G; Mancia, G; Mangoni, AA; Pozzi, M; Stella, ML; Turrini, D, 1995) |
| "Chronic congestive heart failure is one of the risk groups of acquired hypercoagulant and hyperviscous state." | ( Mayer, J; Novotný, J; Spinar, J; Spinarová, L; Vítovec, J, 1995) |
| "Congestive heart failure is characterized by avid sodium retention and a blunted renal response to exogenous and endogenous atrial natriuretic peptide." | ( Abassi, ZA; Golomb, E; Keiser, HR; Kotob, S; Pieruzzi, F, 1995) |
| "Congestive heart failure is closely related to myocardial sympathetic nerve function." | ( Azuma, A; Ito, K; Kohno, Y; Miyao, K; Nakagawa, M; Ohtsuki, K; Shiga, K; Sugihara, H; Taniguchi, Y; Terada, K, 1995) |
| "Congestive heart failure is associated with chronotropic and inotropic hyporesponsiveness to adrenergic stimulation." | ( Bilezikian, JP; Goldsmith, RL; Gratch, M; Horn, EM; Kukin, ML; McCarty, M; Medina, N; Neuberg, GW; Packer, M; Yushak, M, 1995) |
| "Congestive heart failure is characterized by profound alterations in systemic haemodynamics as well as in neurohumoral profile with activation of the sympathetic nervous system, reninangiotensin axis, plasma vasopressin and atrial natriuretic peptides, i." | ( Grassi, G; Mancia, G, 1994) |
| "Congestive heart failure is a complex disorder with a poor long-term prognosis." | ( Miller, MM, 1994) |
| "Congestive heart failure is a condition associated with increased plasma norepinephrine levels, which have been demonstrated to impair glucose handling." | ( D'Amore, A; D'Onofrio, F; Galzerano, D; Gambardella, A; Paolisso, G; Rubino, P; Teasuro, P; Varricchio, M; Verza, M, 1994) |
| "Congestive heart failure is associated with impaired hemodynamic performance and reduced mechanical efficiency." | ( Bersin, RM; Chatterjee, K; de Marco, T; Henderson, GN; Khorrami, P; Klinski, C; Kwasman, M; Lau, D; Tanaka, K; Wolfe, C, 1994) |
| "Congestive heart failure is a clinical syndrome characterized by increased cardiac volume and pressure overload with an inability to excrete a sodium load, which is associated with increased activity of systemic neurohumoral and local autocrine and paracrine mechanisms." | ( Brandt, RR; Burnett, JC; Redfield, MM; Wright, RS, 1993) |
| "Congestive heart failure is a clinical syndrome characterized by neuroendocrine activation." | ( Cohn, JN; Francis, GS; Goldman, S; Johnson, G; Rector, TS; Simon, A, 1993) |
| "Congestive heart failure is a condition often requiring repeated admission to hospital." | ( Levinoff Roth, SN; Moe, G, 1993) |
| "Congestive heart failure is a frequent disorder with an estimated prevalence of 0." | ( Buser, P; Osswald, S; Pfisterer, M; Rickenbacher, P, 1996) |
| "Congestive heart failure is a frequent cardiovascular disease with a poor prognosis in advanced stages." | ( Binggeli, C; Noll, G; Wenzel, RR, 1996) |
| "Congestive heart failure is the final common pathway of diverse etiologies that result in impaired systolic and diastolic function, deleterious activation of neurohumoral pathways, and high morbidity and mortality." | ( Wagoner, LE; Walsh, RA, 1996) |
| "Congestive heart failure is characterized by contractile dysfunction and frequent complex ventricular ectopy." | ( Adams, KF; Patterson, JH; Sueta, CA, 1995) |
| "Congestive heart failure is a major public health problem in Western countries." | ( Doughty, RN; Sharpe, N, 1997) |
| "Congestive cardiac failure is characterized by an increasing activation of the sympathetic nerve activity, the renin angiotensin aldosterone system, vasopressin and endothelin." | ( Luchner, A; Muders, F; Riegger, GA, 1996) |
| "Terminal cardiac failure is a complex syndrome implicating a number of non-cardiac abnormalities." | ( Bareiss, P; Roul, G, 1996) |
| "Congestive heart failure is a clinical syndrome in which the capacity of the heart to maintain cardiac output is impaired." | ( Ceconi, C; Confortini, R; Curello, S; Ferrari, F; Ferrari, R; Pepi, P; Visioli, O, 1996) |
| "Survival in congestive heart failure is related to plasma catecholamines and atrial natriuretic peptide at rest, but the prognostic importance of changes during exercise is unknown." | ( Christensen, NJ; Christiansen, E; Keller, N; Madsen, BK, 1995) |
| "Congestive heart failure is a clinical condition associated with alterations in the normal balance of neurohumoral agents and factors acting on the vascular wall." | ( Altieri, PI; Crespo, MJ; Escobales, N, 1997) |
| "The possibility that congestive heart failure is in part a humoral disease is reviewed here and consequently pharmacologic treatment aimed at reducing the effects of the neuroendocrine response as to be advantageous for patients with heart failure." | ( Cargnoni, A; Ceconi, C; Curello, S; Ferrari, R, 1998) |
| "Chronic congestive heart failure is a common, often lethal disorder of cardiac contractility." | ( Altschuld, RA; Hashimoto, K; Marbán, E; McCune, S; Pérez, NG, 1999) |
| "Since congestive heart failure is associated with various metabolic abnormalities including a deficiency of carnitine, we examined the effects of propionyl L-carnitine, a carnitine derivative, in animals with congestive heart failure." | ( Dhalla, KS; Dhalla, NS; Ferrari, R; Ganguly, PK; Sethi, R, 1999) |
| "Congestive heart failure is characterized by a skeletal muscle myopathy with muscle bulk loss." | ( Ambrosio, GB; Libera, LD; Sandri, M; Vescovo, G; Zennaro, R, 1999) |
| "Congestive heart failure is associated with cardiac adrenergic nerve terminal changes and beta-adrenoceptor density downregulation." | ( Armstrong, J; Dong, E; Hagen, J; Kawai, H; Liang, CS; Mohan, A; Stevens, SY, 2000) |
| "In the elderly, congestive heart failure is common and associated with significant morbidity and mortality." | ( Fidelman, Z; Korshun, Z, 2000) |
| "Congestive heart failure is a progressive disease with significant morbidity and mortality." | ( Haji, SA; Movahed, A, 2000) |
| "Congestive heart failure is a complex syndrome and one of the major cardiological problems of our time." | ( Avendaño, C; Gutiérrez-Iñiguez, MA; Marín, E; Marín, J; Rodríguez-Martínez, MA, 2000) |
| "Congestive heart failure is a most arrhythmogenic disease that is responsible for many unexpected sudden deaths." | ( Seelig, MS, 2000) |
| "Congestive heart failure is associated with impaired endothelial function in the peripheral systemic vasculature and with systemic release of inflammatory cytokines." | ( Dimmeler, S; Freyssinet, JM; Haendeler, J; Hugel, B; Mallat, Z; Rössig, L; Tedgui, A; Zeiher, AM, 2000) |
| "The advances in cardiac failure are permanent." | ( Juillière, Y, 2001) |
| "We conclude that congestive heart failure is a risk of treatment with doxorubicin for Wilms' tumor." | ( Breslow, NE; D'Angio, GJ; Green, DM; Grigoriev, YA; Nan, B; Norkool, PA; Takashima, JR, 2001) |
| "Prognosis in congestive heart failure is directly linked to neurohormonal activation." | ( Miller, AB; Srivastava, P, 2001) |
| "Congestive heart failure is characterized by high levels of norepinephrine which is considered to be arrhythmogenic." | ( Baartscheer, A; de Bakker, JM; de Jonge, N; Opthof, T; Schumacher, C; van Ginneken, AC; Veldkamp, MW; Verkerk, AO, 2001) |
| "Congestive heart failure is characterized by a sympathetic activation that is coupled with a baroreflex impairment." | ( Bertinieri, G; Grassi, G; Mancia, G; Pierini, A; Seravalle, G; Turri, C, 2001) |
| "Human congestive heart failure is characterized by complex neurohumoral activation associated with the up-regulation of vasoconstricting and salt-retaining mediators and the compensatory rise of counter-regulatory hormones." | ( Armbruster, FP; Bartsch, C; Baumann, G; Dschietzig, T; Laule, M; Richter, C; Stangl, K, 2001) |
| "The risk for congestive heart failure is strongly increased in diabetes, and the prognosis of diabetic patients with established heart failure is worse compared to nondiabetic patients." | ( Aronson, D; Burger, AJ, 2001) |
| "Congestive heart failure is characteristically associated with systemic vasoconstriction and impaired vasodilatory capacity, leading to decreased peripheral perfusion." | ( Akhter, W; Elkayam, U; Mehdi, S; Nikitina, A; Prakash, M; Subbiah, S, 2001) |
| "Congestive heart failure is a major health problem in the diabetic." | ( Lopaschuk, GD, 2002) |
| "Cardiac failure is a common feature in the evolution of cardiac disease." | ( Beggah, AT; Bocchi, B; Cailmail, S; Delage, V; Delcayre, C; Escoubet, B; Farman, N; Jaisser, F; Ouvrard-Pascaud, A; Peuchmaur, M; Puttini, S, 2002) |
| "Chronic cardiac failure is often associated with sleep respiratory disorders." | ( Escourrou, P; Pellerin, D, 2002) |
| "Skeletal muscle in congestive heart failure is responsible for increased fatigability and decreased exercise capacity." | ( Angelini, A; Calvani, M; Dalla Libera, L; Della Barbera, M; Dona, M; Gobbo, V; Mosconi, L; Peluso, G; Ravara, B; Sandri, M; Vescovo, G, 2002) |
| "Congestive heart failure is associated with hyperuricemia and elevations in the levels of circulating markers for inflammation." | ( Gonsorcík, J; Kisel'ová, J; Olejníková, M; Olexa, P; Olexová, M; Tkác, I, 2002) |
| "The incidence of congestive heart failure is higher in diabetic patients, although the reasons for this increased rate are debated (higher incidence and severity of coronary heart disease and arterial hypertension, or a true diabetic cardiomyopathy)." | ( Anguita Sánchez, M, 2002) |
| "Congestive heart failure is extremely common in octogenarians and is associated with severe fatigue, shortness of breath, recurrent hospitalizations, and death." | ( Blum, M; Iaina, A; Keren, G; Schwartz, D; Sheps, D; Silverberg, DS; Wexler, D, 2003) |
| "Congestive heart failure is a major public health problem in the United States, Canada, and other Western countries." | ( Collins, JF; Egan, D; Garg, R; Geller, N; Williford, WO; Yusuf, S, 2003) |
| "Furthermore, congestive heart failure is associated with impaired creatinine clearance and increased urea and urate, and osteoporosis and hip fractures are characterized by low albumin and cholesterol." | ( Berg, S; Evrin, PE; Johansson, B; McClearn, G; Nilsson, SE; Takkinen, S; Tryding, N, 2003) |
| "Congestive heart failure is found in about one-quarter of cases of chronic kidney disease." | ( Blum, M; Iaina, A; Schwartz, D; Silverberg, D; Wexler, D, 2004) |
| "Congestive heart failure is a syndrome that is usually initiated by a reduction in pump function of the heart, i." | ( Gao, L; Qian, ZM; Tan, W; Wang, W; Zhu, GQ, 2004) |
| "Chronic congestive heart failure is associated with abnormal HRT." | ( Chan, HL; Du, CC; Hwang, JJ; Lai, LP; Lin, JL; Lin, LY; Tseng, YZ, 2004) |
| "Congestive heart failure is a common condition with a poor prognosis." | ( Feldman, AM, 2004) |
| "Congestive heart failure is associated with a loss of circadian and short-term variability in blood pressure and heart rate." | ( Engelhardt, S; Janssen, BJ; Lemmer, B; Lohse, M; Witte, K, 2004) |
| "Cardiac failure is one of the leading causes of mortality in developed countries." | ( Pollesello, P; Solaro, RJ; Sorsa, T, 2004) |
| "Advanced congestive heart failure is associated with activation of the renin-angiotensin system and skeletal muscle wasting." | ( Delafontaine, P; Du, J; Li, Y; Mitch, WE; Rosenthal, N; Song, YH, 2005) |
| "Congestive heart failure is a leading cause of morbidity and mortality throughout the world and is now the leading cause of hospitalizations in adults over 65 years of age with an estimated annual expenditure in excess of USD 20 billion." | ( Januzzi, JL; O'Donoghue, M, 2005) |
| "Cardiac failure is a prevalent and costly condition in Western society." | ( Jeremy, R; Sullivan, DR; West, M, 2005) |
| "Although congestive heart failure is rare in the case of drug-induced hypereosinophilia, it is one of life-threatening complications." | ( Akiyama, O; Hagiwara, K; Matsuno, H; Sato, T, 2005) |
| "Patients with congestive heart failure are at risk for hiperkaliemia because of coexisting comorbidities and use of multiple medications that impair potassium excretion--such as angiotensin-converting enzyme inhibitors or spironolactone." | ( Bułło, B; Konopa, J; Rutkowski, B, 2005) |
| "Congestive heart failure is increasing in prevalence and represents a major public health problem." | ( Akao, M; Delafontaine, P, 2006) |
| "Congestive heart failure is a pathologic condition characterized by progressive decrease in left ventricular contractility and consequent decline of cardiac output." | ( Aras, O; Dilsizian, V; Eckelman, WC; Messina, SA; Shirani, J, 2007) |
| "Congestive heart failure is increasing in prevalence in the United States, and associated morbidity and mortality remain high." | ( Abraham, WT; Hiestand, B, 2007) |
| "Congestive heart failure is the most common cause of death in patients with thalassemia, as chronic accumulation of iron due to regular blood transfusions leads to biventricular systolic dysfunction and death at a very young age." | ( Davison, G; Jabbar, DA; Muslin, AJ, 2007) |
| "Congestive heart failure is a growing public health problem worldwide, particularly in the elderly population, in whom it has a substantial impact on quality of life and survival." | ( Brunner-La Rocca, HP; Leibundgut, G; Pfisterer, M, 2007) |
| "1." | ( Vakil, RJ, 1949) |
| "Congestive heart failure is associated with a decrease in LZ+ MYPT1 expression, which results in a decrease in the sensitivity to cGMP-mediated smooth muscle relaxation." | ( Brozovich, FV; Ogut, O, 2008) |
| "For this reason congestive heart failure is an increasingly widespread, costly and deadly disease, frequently named as epidemic of the XXI century." | ( Barsotti, A; Di Napoli, P, 2009) |
| "Congestive heart failure is a risk factor for ischemic stroke." | ( Aoki, J; Iguchi, Y; Kimura, K; Okada, Y; Shibazaki, K; Terasawa, Y, 2009) |
| "Post-cardiotomy cardiac failure is more common in patients with a low preoperative left ventricular ejection fraction (LVEF)." | ( Kirkeby-Garstad, I; Kolseth, SM; Nordhaug, DO; Sellevold, O; Stenseth, R; Wahba, A, 2009) |
| "The incidence of congestive heart failure is 3-fold greater than that of acute coronary syndrome in haemodialysis (HD) patients." | ( Burns, K; Chan, K; Doucette, SP; Hiremath, S; Richardson, R; Zimmerman, D, 2010) |
| "Congestive heart failure is a syndrome characterized by decreased cardiac output with consequent neurohormonal activation leading to water and salt retention." | ( Torre-Amione, G; Youker, K, 2009) |
| "Cardiac failure is the most prevalent cause of death at higher age, and is commonly associated with impaired energy homeostasis in the heart." | ( Isken, F; Kuhlow, D; Laube, B; Pfeiffer, AF; Ristow, M; Schomburg, L; Schulz, TJ; Thierbach, R; Tschöpe, C; Voigt, A; Westermann, D; Zarse, K, 2010) |
| "Congestive heart failure is a major cause of morbidity and mortality in diabetes." | ( Andrén, B; Berne, C; Holst, JJ; Ingelsson, E; Lind, L; Nathanson, D; Nyström, T; Zethelius, B, 2011) |
| "Cardiac failure is a rare complication of treatment." | ( Andre, M; Bizien, N; Grassin, F; Paleiron, N; Vinsonneau, U, 2011) |
| "Congestive heart failure is associated with impaired renal function." | ( Abassi, Z; Abu-Saleh, N; Awad, H; Bishara, B; Goltsman, I; Khamaysi, I; Ramadan, R, 2011) |
| "Congestive heart failure is a very real public health issue not only in the United States, but worldwide." | ( Dohadwala, M; Estes, NA; Link, MS, 2011) |
| "Congestive heart failure is common in patients with chronic kidney disease, but the association of serum sodium concentration with mortality in such patients is not well characterized." | ( Kalantar-Zadeh, K; Kovesdy, CP; Lott, EH; Lu, JL; Ma, JZ; Malakauskas, SM; Molnar, MZ, 2012) |
| "Congestive heart failure is an inexorable disease associated with unacceptably high morbidity and mortality." | ( Gao, MH; Hammond, HK; Tang, T, 2012) |
| "Human congestive heart failure is accompanied by structural and electrical alterations leading to the development of an arrhythmogenic substrate." | ( Müller, FU; Schulte, JS; Seidl, MD, 2014) |
| "Cardiotoxicity and congestive heart failure are the major factors that limit the use of anti-neoplastic drug adriamycin (ADR)." | ( El-Boghdady, NA, 2013) |
| "Congestive heart failure is underdiagnosed in patients with chronic obstructive pulmonary disease (COPD)." | ( Brekke, PH; Høiseth, AD; Karlsson, BD; Omland, T; Søyseth, V, 2013) |
| "Congestive heart failure is an important cause of endotoxin resorption from the intestine, which significantly increases PCT expression in noninfected patients with heart failure." | ( Ge, N; Liu, J; Liu, W; Wang, W; Wen, D; Yuan, H; Zhang, P; Zhang, X, 2014) |
| "High output cardiac failure is rare in MD patients and is related to myocardial abnormalities and hyperlactacidemia." | ( Horii, M; Kamon, D; Kawakami, R; Nakagawa, H; Nakano, T; Okayama, S; Onoue, K; Saito, Y; Sakaguchi, Y; Takemura, G; Uemura, S, 2014) |
| "Cardiac failure is a major cause of mortality and morbidity worldwide, since the standard treatment for cardiac failure in the clinical practice is chiefly to focus on removal of insults against the heart or minimisation of additional factors to exacerbate cardiac failure, but not on regeneration of the damaged cardiac tissue." | ( Fukushima, S; Miyagawa, S; Sakai, Y; Sawa, Y, 2015) |
| "Male sex and congestive heart failure are risk factors for further renal function decline in patients developing CIN after PVI." | ( Al Adas, Z; Kabbani, LS; Lodewyk, K; Nypaver, TJ; Qureshi, S; Robinson, D; Shepard, AD; Sullivan, B; Weaver, MR, 2019) |
| "Congestive heart failure is characterized by suppressed cardiac output and arterial filling pressure, leading to renal retention of salt and water, contributing to further volume overload." | ( Basu, S; Hallow, KM; Yu, H, 2020) |
| "Congestive heart failure is a serious chronic condition when the heart's muscles become too damaged and a condition in which one or both ventricles cannot pump sufficient blood to meet the metabolic needs of the body." | ( Biresaw, HB; Hussen, NM; Workie, DL, 2022) |
| Excerpt | Reference |
|---|
| "7 consecutive patients with congestive heart failure refractory to standard therapy were treated with nitroglycerin ointment (GTNO)." | ( Chandraratna, PA; Langevin, E; O'Dell, R; Rubenstein, C; San Pedro, S, 1978) |
| "Ten patients with severe congestive heart failure after acute myocardial infarction were treated with 40 mg isosorbiddinitrate-retard every 4 hours and additional sublingual nitroglycerine." | ( Baitsch, G; Bertel, O; Burkart, F; Elsässer, S; Ritz, R, 1978) |
| "A case of congestive heart failure in a child with Wilms' tumor treated Adriamycin is presented and discussed." | ( Heller, RM; Kaizer, H; Musikabhumma, A; Sang Oh, K, 1976) |
| "chronic congestive heart failure refractory to therapy with glycosides and diuretics." | ( Kübler, W; Mäurer, W; Tillmanns, H, 1979) |
| "In 10 hospitalized patients with severe congestive heart failure refractory to standard medical therapy for three days, low dose intravenous dopamine (2-4 micrograms/kg/min) was infused for 48 h." | ( Crawford, MH; O'Rourke, RA; White, DH, 1979) |
| "14 patients with congestive heart failure requiring diuretic therapy were randomly assigned to treatment with ticrynafen (TCRN) 250 mg or hydrochlorothiazide (HCTZ) 50 mg once or twice daily." | ( Clements, P; Smith, JW, 1979) |
| "Chronic congestive heart failure not controlled by conventional therapy was treated with intravenous amrinone, a new non-glycosidic, non-catecholamine cardiotonic agent." | ( Alousi, AA; Davis, R; Davolos, D; Keung, E; LeJemtel, TH; Matsumoto, M; Ribner, HS; Schwartz, W; Sonnenblick, EH, 1979) |
| "In three neonates with cardiac failure and coarctation the cutaneous PO2 (cPO2) has been measured during the administration of a high concentration of oxygen." | ( Benoît, M; de Geeter, B; Messer, J; Willard, D, 1979) |
| "Four dogs with congestive heart failure associated with dirofilariasis and mitral valvular incompetence initially responded to treatment with digoxin or etamiphylline camsylate, and frusemide but became refractory to this therapy and were in cardiac decompensation." | ( Atwell, RB, 1979) |
| "A patient with compensated congestive heart failure suffered acute deterioration of her renal function and cardiac status, requiring peritoneal dialysis, in association with indomethacin therapy." | ( Venuto, RC; Walshe, JJ, 1979) |
| "Optimal therapy for congestive cardiac failure requires identification of correctable factors that aggravate it as well as an understanding of its etiology." | ( Armstrong, PW, 1979) |
| "Irreversible cardiac failure occurred nine months after starting treatment, and was considered to be due to the toxic effects of the compound." | ( Benoit, P; Fontaliran, F; Gay, J; Gerbaux, A; Montely, JM, 1979) |
| "Ten patients with congestive heart failure, on full digitalis treatment, were given TA (dose range 250-1000 mg/die): in each patient a prompt diuretic effect was observed, associated to a significant reduction of body weight and to a marked improvement of the clinical signs of heart failure." | ( Agabiti-Rosei, E; Alicandri, C; Corea, L; Fariello, R; Muiesan, G; Oldoni, T, 1979) |
| "Ten patients in severe cardiac failure were treated with dopamine (4 microgram/kg ." | ( Davidson, J; Delius, W; Himmler, C; Klein, G; Volger, E; Wirtzfeld, A, 1978) |
| "A patient with severe, chronic congestive heart failure was unresponsive not only to conventional therapy, but also to nonparenteral nitroglycerin and isosorbide dinitrate; he became nitroprusside dependent." | ( Chatterjee, K; Drew, D; Klausner, SC; Parmley, WW; Polansky, J; Zacherle, B, 1976) |
| "They give rise to cardiac failure, which is more marked when the rate is high (180-260/mn) and particularly resistant to treatment." | ( Attuel, P; Batisse, A; Brechenmacher, C; Bretagne, J; Clementy, J; Coumel, P; Fidelle, JE; Gérard, R; Grolleau, R; Huault, G; Kachaner, J; Mouy, A; Nouaille, J; Ribiere, M; Toumieux, MC, 1976) |
| "The case demonstrates that clearly acute congestive heart failure and its treatment may dramatically affect the kinetics of theophylline elimination." | ( Chick, TW; Jenne, JW; Miller, BA; Strickland, RD, 1977) |
| "Patients suffering from congestive heart failure were treated with Digitalis, other patients with normal hearts were subjected to infusion therapy of Isoproterenol, Propranolol, Verapamil and Calcium chloride." | ( Stefan, G, 1976) |
| "A group of 115 congestive heart failure patients were hospitalized, given a comprehensive medical examination and treated with placebo for four weeks." | ( Exaire, JE; Figueroa, G; Hamdan, G; Villalpando, J, 1975) |
| "Two patients were treated for cardiac failure but failed to show improved myocardial function." | ( Helton, WC; Hornung, JR; Hunt, CE; Johnson, FW; Lindsay, WG; Nicoloff, DM; Pyle, RB; Trumball, HR, 1975) |
| "Eight patients with chronic congestive heart failure (four with cardiomyopathy and four with ischemic heart disease) underwent hemodynamic studies during acute administration of digoxin, given intravenously in two 0-5 mg doses 2 hours apart." | ( Cohn, K; Goldschlager, N; Karpman, LS; Kersh, ES; Selzer, A, 1975) |
| "In the majority of patients with congestive heart failure insulin secretion was reduced both after fasting and after glucose administration." | ( Dudaev, VA; Korochkin, IM; Oganov, RG; Rybina, GI; Vinogradova, IV, 1975) |
| "In contrast, cardiac failure caused by volatile anesthetics proved to be resistant to this therapy." | ( Höring, HJ, 1975) |
| "Twelve patients with congestive heart failure receiving maintenance therapy with digoxin and potent diuretics were followed closely during development of hypokalemia and potassium loss." | ( Olesen, KH; Steiness, E, 1976) |
| "Forty patients with congestive heart failure or hypertensive heart disease were given long-term maintenance treatment with a combined bumetanide/slow-release potassium supplement preparation ('Burinex K')." | ( Singh, BB; Watt, DA, 1976) |
| "Other facilitating factors included cardiac failure, pre-existing chronic renal insufficiency, combined therapy with non-steroidal anti-inflammatory drugs, and diabetes mellitus." | ( Bridoux, F; Fleury, D; Hazzan, M; Kleinknecht, D; Lemaitre, V; Pallot, JL; Vanhille, P, 1992) |
| "A patient with congestive cardiac failure developed a rash following captopril treatment." | ( Holt, PJ; Long, CC; Wong, SS, 1992) |
| "Thus, patients with severe chronic congestive heart failure display metabolic derangement in muscle, which, in this study, was not corrected by treatment with enalapril." | ( Broqvist, M; Dahlström, U; Karlsson, E; Larsson, J, 1992) |
| "1 patient developed severe congestive heart failure 12 months from the end of therapy." | ( Aitini, E; Cantore, M; Cavazzini, G; Di Marco, A; Rabbi, C; Rivera, A; Smerieri, F; Togliani, B, 1992) |
| "Flosequinan therapy in patients with congestive heart failure results in a sustained beneficial hemodynamic action and improved cardiac performance without an increase in metabolic demand or activation of the sympathetic nervous system." | ( Cavero, PG; Chatterjee, K; De Marco, T; Kwasman, M; Lau, D; Liu, M, 1992) |
| "The clinical signs of congestive heart failure resolved rapidly on treatment with captopril and myocardial performance became normal within two weeks of medical treatment with captopril for one week and with captopril in combination with phenoxybenzamine for another week." | ( Ritz, R; Salathe, M; Weiss, P, 1992) |
| "One patient, who remained in mild cardiac failure with digitalis therapy, died suddenly at the age of 9 years." | ( Dupuis, C; Khanoyan, P; Rey, C; Schleich, JM; Vaksmann, G, 1992) |
| "The reduction in mortality from cardiac failure was demonstrated in the Veterans I Study in association with Hydralazine compared to conventional digitalo-diuretic therapy but seems less important than that obtained by angiotensin converting enzyme inhibitors." | ( Isnard, R; Komajda, M; Lechat, P, 1992) |
| "In 9 patients with chronic congestive heart failure, 5 patients (55%) moved to a lower NYHA class and the overall condition was improved in 6 patients (66%) after treatment with l-carnitine." | ( Kobayashi, A; Masumura, Y; Yamazaki, N, 1992) |
| "Thus, patients with severe chronic congestive heart failure, New York Heart Association functional class IV, displayed disturbed electrolyte and water content in muscle, which, in this study, was not corrected by treatment with enalapril." | ( Broqvist, M; Dahlström, U; Karlsson, E; Larsson, J, 1992) |
| "In the long-term therapy of chronic congestive heart failure ibopamine has been useful in mobilization of edema in acute decompensation, improvement of symptoms according to the New York Heart Classification and of exercise tolerance." | ( Kleber, FX, 1991) |
| "Thirty-two patients with chronic cardiac failure underwent 24-hour ambulatory electrocardiographic monitoring on 2 separate occasions: 20 patients before and during treatment with captopril, and 12 acting as controls." | ( Ewing, DJ; Flapan, AD; Neilson, JM; Nolan, J, 1992) |
| "Six patients with chronic congestive cardiac failure, who had never received any drug treatment, were studied before and after one month of therapy with frusemide alone at a dose of 40 mg a day." | ( Anand, IS; De Giuli, F; Ferrari, R; Harris, P; Kalra, GS; Panzali, A; Poole-Wilson, PA, 1991) |
| "Eleven patients with congestive heart failure class II-IV (NYHA) caused by ischemic heart disease were studied before and three months after adding enalapril to their treatment with furosemide." | ( Bann, J; Baur, LH; Bruschke, AV; Buis, B; Manger Cats, V; Schipperheyn, JJ; van der Laarse, A; van der Wall, EE; van Dijk, AD, 1991) |
| "Preliminary results in patients with cardiac failure suggest that this drug may reduce cardiac arrhythmias and may allow the reduction of digoxin therapy." | ( Pepine, CJ, 1991) |
| "In 25 patients whose chronic congestive heart failure (CHF) had recently worsened to New York Heart Association class IV, pimobendan (5 to 20 mg/day) was added to maximum conventional therapy consisting of digoxin, diuretics, angiotensin-converting enzyme inhibitors, coumadin derivatives to prevent thromboembolic complications, and amiodarone to suppress serious ventricular rhythm disturbances." | ( Hagemeijer, F, 1991) |
| "Nineteen infants with symptoms of congestive heart failure due to a VSD were studied with load-independent indexes during 4 study periods: (1) before any medication; (2) while on chronic diuretics; (3) while on both diuretics and digoxin; and (4) while on diuretics alone, to determine if digoxin: (a) increases "contractility" when added to diuretic therapy; and (b) improves symptoms." | ( Daniels, SR; Hannon, DW; Kimball, TR; Meyer, RA; Schwartz, DC; Shukla, R; Tian, J, 1991) |
| "Digoxin is commonly used to treat congestive heart failure." | ( Coletta, D; Forman, DE; Kenny, D; Kosowsky, BD; Pastore, JO; Rohrer, M; Stoukides, J, 1991) |
| "Relief of the signs and symptoms of congestive heart failure and improvement in functional status have also been demonstrated in xamoterol-treated patients." | ( Heng, MK, 1990) |
| "Eleven patients had congestive heart failure within one year of treatment with doxorubicin; five of them had recurrent heart failure 3." | ( Colan, SD; Gelber, RD; Lipshultz, SE; Perez-Atayde, AR; Sallan, SE; Sanders, SP, 1991) |
| "Treatment of congestive heart failure depends on the cause, precipitating factors, and symptoms of the disease in each patient." | ( Kahn, JK, 1991) |
| "This report describes 4 patients with congestive heart failure who developed severe renal insufficiency secondary to either enalapril or captopril therapy in the absence of any currently recognized predisposing factors." | ( Carson, P; Odum, J; Russell, G, 1991) |
| "A small number of patients with congestive heart failure (CHF) have been treated with quinapril." | ( Cetnarowski-Cropp, AB, 1991) |
| "21 patients with symptoms of chronic congestive heart failure, NYHA classes II-IV, were treated with digoxin and furosemide for at least 14 days." | ( Kochmański, M; Zochowski, RJ, 1990) |
| "The aims of treatment of cardiac failure are diverse depending on whether treatment is directed to correct the initial myocardial disease, its myocardial consequences, its circulatory consequences or, more simply, the patient's symptoms." | ( Castaigne, A; Dubois-Randé, JL; Dutoit, C; Duval-Moulin, AM; Merlet, P; Perchet, H; Saal, JP, 1990) |
| "In 22 of 27 cases of congestive heart failure (CHF) treated with nifedipine (NIF), significant improvements in resting hemodynamics were noticed." | ( Chen, DG; Chen, K; Feng, QP; Wang, ZQ, 1990) |
| "Twenty-five patients with congestive heart failure (CHF) underwent a double-blind randomized study of the acute hemodynamic effects of orally administered nicorandil, a newly developed vasodilator drug." | ( Binkley, PF; Cody, RJ; Leier, CV; Moeschberger, ML; Mohrland, JS; Tice, FD; Wolf, DL, 1990) |
| "A total of 71 patients with cardiac failure requiring diuretic treatment were randomly allocated to receive either 20 mg frusemide/2." | ( Allman, S; Norris, RJ, 1990) |
| "The GIK therapy improved congestive heart failure following elevation of cardiac output in 7 cases, and simultaneously stabilized the serum glucose level within the range of 88-175 mg/dl." | ( Horimoto, C; Tsujimura, M; Tsutsumi, K, 1990) |
| "Conventional therapy for congestive heart failure (CHF) includes sodium-restricted diet, diuretics, digitalis, vasodilators, and short-term intravenous administration of beta-adrenergic agonists during episodes of decompensation." | ( Galvao, M, 1990) |
| "Patients with congestive heart failure (CHF) often have volume expansion and are receiving digoxin therapy." | ( Dasgupta, A; Heimann, P; Saldana, S, 1990) |
| "Thus, the diuretic monotherapy of congestive heart failure with piretanide is highly effective and shows a significant improvement in all clinical and hemodynamic parameters in the absence of any remarkable side effects." | ( Bauer, U; Cernoch, K; Fehske, KJ; Haerer, W; Hetzel, M; Hombach, V; Mouselimis, N; Stauch, M; Sultan, N, 1990) |
| "Eleven patients with refractory class IV congestive heart failure who were not candidates for cardiac transplantation were given iv dobutamine therapy on an outpatient basis." | ( Herrmann, V; Merkle, EJ; Miller, LW, 1990) |
| "Inotropic and vasodilator therapy for congestive heart failure improve left ventricular systolic performance by different mechanisms." | ( Campbell, CA; Held, AC; Johnson, V; Lavine, SJ, 1990) |
| "The patients with congestive heart failure which were treated by combination of digoxin with cyclovirobuxine D were described, with good result, of which prominating effect was 45." | ( Yan, M, 1990) |
| "In 12 patients with severe congestive heart failure (NYHA class III-IV), treated with digitalis and diuretics, we performed a baseline evaluation through a right heart catheterization, echocardiography and radionuclide ventriculography." | ( Candela, B; Mercurio, G; Messina, L; Raineri, A; Rotolo, A; Traina, M; Trapani, R, 1990) |
| "Patients with cardiac failure undergoing prolonged intensive therapy are prone to develop hypomagnesemia." | ( Bilotta, F; Caprettini, S; De Vito, A; Sandoz, W; Viola, R; Voci, P; Wagner, SL, 1990) |
| "This patient demonstrated symptoms of congestive heart failure 2 months after the last intravenous administration." | ( Hori, M; Inui, M; Ishida, Y; Kamada, T; Kimura, K; Kitabatake, A; Kondo, H; Kozuka, T; Morozumi, T; Tani, A, 1990) |
| "Which patients with chronic congestive heart failure who are the most likely to benefit from therapy with the novel inotropic agents, and the therapeutic limitations of these agents are discussed." | ( Keren, G; LeJemtel, TH; Reis, D; Sonnenblick, EH, 1986) |
| "Clinical trials in patients with congestive heart failure have shown a wide disparity in the hemodynamic responses to chronic therapy with newer positive inotropic drugs." | ( Gilfrich, HJ; Römer, A; Witzke-Gross, J, 1989) |
| "Twenty patients with moderately severe congestive heart failure were randomized to chronic enoximone (n = 10) or placebo (n = 10) therapy in a double-blind manner and serially evaluated over a 16-week-period." | ( Binkley, PF; Huss-Randolph, P; Leier, CV; Starling, RC, 1989) |
| "A patient with congestive heart failure and mild renal impairment developed exfoliative dermatitis following the addition of captopril to her therapy." | ( Bolli, R; Charlat, ML; O'Neill, PG; Rajan, N, 1989) |
| "In studies of patients with refractory congestive heart failure, acute favorable hemodynamic effects were demonstrated after the administration of quinapril." | ( Posvar, E; Sedman, AJ, 1989) |
| "11 infants and children with severe congestive heart failure after cardiac surgery were treated with Amrinone." | ( Seiffert, P; Wessel, A, 1989) |
| "Twenty-seven cases of congestive heart failure (CHF) were treated with nifedipine (Nif) 20 mg po." | ( Chen, DG; Chen, K; Feng, QP; Wang, ZQ, 1989) |
| "Revision of ten cases of congestive heart failure who was administered metolazona after inadequate response to furosemide." | ( Correia, JM; Loureiro, PA, 1989) |
| "Twenty patients with severe chronic cardiac failure caused by ischaemic heart disease were treated with flosequinan 100 mg daily or placebo in addition to their existing treatment with diuretics and, in some, digoxin in a randomised double blind trial." | ( Elborn, JS; Nicholls, DP; Stanford, CF, 1989) |
| "The prevalence of congestive heart failure (CHF) and its progressive degenerative course continue to generate pressure for alternative, more effective means of treatment." | ( Baptista, RJ; Mitrano, FP; Perri-LaFrancesca, J, 1989) |
| "Nineteen patients with congestive heart failure caused by such conditions as acute myocardial infarction, valvular disease and dilated cardiomyopathy were examined before and after treatment with diuretics, digitalis and vasodilators." | ( Asakura, S; Asano, Y; Hosoda, S; Muto, S; Tabei, K, 1989) |
| "32 dogs with congestive heart failure without sufficient reaction to a standardized therapy with glycosides are treated with an individual glycoside dose." | ( Staudacher, G, 1989) |
| "Ten patients with stage 3 or 4 congestive heart failure (New York Heart Association class) and secondary mitral regurgitation were studied before and during intravenous administration of dobutamine (mean dose, 7." | ( Keren, G; Laniado, S; Lejemtel, TH; Sonnenblick, EH, 1989) |
| "The successful treatment of congestive heart failure with intravenous dopamine in the acute setting has prompted investigation into the development and use of oral dopamine analogs." | ( Broderick, G; Rajfer, SI, 1989) |
| "In patients with congestive heart failure resistant to conventional therapy, lisinopril 2." | ( Lancaster, SG; Todd, PA, 1988) |
| "In 3 patients with severe cardiac failure high dose therapy with the ACE inhibitor enalapril was instituted during a state of extracellular volume depletion." | ( Stäubli, M; Wieland, T, 1988) |
| "Down-regulation of beta receptors in congestive heart failure results in a decrease or loss of efficacy of beta-adrenergic receptor agonists on long-term administration." | ( Kopia, GA; Ruffolo, RR, 1986) |
| "Careful differential diagnosis of congestive heart failure is a critical pre-condition to starting any therapy for heart failure, particularly in the elderly patient." | ( Goldsmith, SR; Marx, S, 1988) |
| "The classical therapy of congestive heart failure (CHF) with inotropic agents (digitalis and newer inotropics) and diuretic agents remains unsatisfactory in many cases." | ( van Zwieten, PA, 1988) |
| "23 horses and one donkey with congestive heart failure are treated with a standardized methyldigoxin dose (0." | ( Staudacher, G, 1989) |
| "It is believed that the treatment of congestive heart failure may convert an associated transudative pleural effusion into a "pseudoexudate." | ( Caldwell, SH; Chakko, SC; Sforza, PP, 1989) |
| "In patients with chronic congestive heart failure, acute myocardial performance was more optimally influenced by MDL 17,043 than dobutamine administration." | ( Hakki, A; Iskandrian, AS; Likoff, MJ; Ulrich, S, 1986) |
| "Patients with acute congestive cardiac failure had elevated plasma concentrations of atrial natriuretic peptide (ANP) which fell towards normal levels with successful diuretic therapy." | ( Anderson, JV; Bloom, SR; Gibbs, JS; Greco, C; Rowland, E; Woodruff, PW, 1986) |
| "Fifteen patients with congestive heart failure (New York Heart Association III) were randomly assigned to treatment with either captopril or ramipril, a newly developed angiotensin converting enzyme inhibitor." | ( Dietz, R; Hackenthal, E; Kübler, W; Manthey, J; Osterziel, KJ; Röhrig, N; Schmidt-Gayk, H, 1987) |
| "In patients with chronic cardiac failure, improvement in ventricular function is observed after the administration of enoximone, a phosphodiesterase inhibitor with inotropic and vasodilator properties." | ( Janicki, JS; Shroff, SG; Weber, KT, 1987) |
| "Twelve patients with moderately severe congestive heart failure underwent the simultaneous determination of central and regional hemodynamics after administration of placebo and enoximone." | ( Leier, CV; Matthews, S; Meiler, SE; Unverferth, DV, 1987) |
| "Eleven patients with acute congestive heart failure were studied during treatment with a loop diuretic." | ( Anderson, JV; Bloom, SR; Woodruff, PW, 1988) |
| "Twenty patients with congestive heart failure were treated at Kitasato University Hospital." | ( Ando, K; Hasegawa, N; Katoh, Y; Kurosawa, T; Marumo, F; Takeda, S, 1988) |
| "Withdrawal of captopril therapy for cardiac failure results in increments in plasma cortisol, noradrenaline and heart rate." | ( Chambers, S; Espiner, EA; Ikram, H; Livesey, JH; Nicholls, MG, 1985) |
| "Patients treated for congestive heart failure with a combination of digoxin and diuretics demonstrated a higher concentration of sodium and chloride in their sweat fluid when compared to age-matched controls." | ( Aladjem, M; Benzon, L; Mor, A, 1985) |
| "Efficacy in treating congestive heart failure and hypertension secondary to renal artery stenosis has also been demonstrated for both angiotensin converting enzyme inhibitors." | ( Cleary, JD; Taylor, JW, 1986) |
| "In patients with severe congestive heart failure resistant to conventional therapy, enalapril improves cardiac performance by a reduction in both preload and afterload, and improves clinical status long term." | ( Heel, RC; Todd, PA, 1986) |
| "Traditionally the treatment of congestive heart failure is based on diuretics, restriction of salt intake, and digitalis." | ( Rutishauser, W, 1986) |
| "In patients with congestive heart failure treated with digitalis, these natriuretic agents are particularly useful because of their potassium-sparing properties." | ( Brunner, HR; Nüssberger, J; Waeber, B, 1988) |
| "Patients with congestive heart failure (CHF) can be treated by diuretics, inotropic agents and vasodilators." | ( Follath, F, 1988) |
| "New or worsened congestive heart failure occurred in seven patients on flecainide therapy, all with an ejection fraction of less than 30%; six had a previous history of compensated heart failure and of these, three died." | ( de Paola, AA; Greenspan, AM; Horowitz, LN; Kay, HR; Morganroth, J; Senior, S; Spielman, SR, 1987) |
| "To evaluate this relationship in chronic congestive heart failure (CHF), we studied eight patients with chronic CHF at baseline and during treatment with nitroglycerin." | ( Amin, D; Jasper, AC; Koerner, SK; Mohsenifar, Z; Shah, PK, 1987) |
| "The severity of cardiac failure, according to the Weber classification, was reduced by acute and chronic therapy." | ( Cobelli, F; Febo, O; Lepore, AM; Luca, C; Opasich, C; Riccardi, G; Specchia, G; Tramarin, R, 1988) |
| "In 14 patients with severe congestive heart failure (CHF) due to ischemic heart disease or idiopathic dilated cardiomyopathy, the hemodynamic response to intravenous infusion of dobutamine (D) was compared to that of a new non-catechol, non-glycoside, inotropic and vasodilator agent, MDL-17,043 (MDL) administered in incremental intravenous doses." | ( Amin, DK; Brandon, G; Hulse, S; Shah, PK; Shellock, FG; Spangenberg, R; Swan, HJ, 1985) |
| "Postpartum congestive heart failure developed in a primigravida seven years after doxorubicin therapy for osteosarcoma." | ( Brown, CE; Davis, LE, 1988) |
| "A patient with congestive heart failure and normal renal function developed anuria during treatment with nifedipine." | ( Chalopin, JM; Eicher, JC; Louis, P; Morelon, P; Rifle, G; Tanter, Y, 1988) |
| "Thirty-five patients with severe chronic congestive heart failure that was refractory to conventional therapy were given high dosages of furosemide (250 to 4000 mg/d) because of significantly reduced renal function (mean endogenous creatinine clearance, 0." | ( Gerlag, PG; van Meijel, JJ, 1988) |
| "Nine patients with severe congestive heart failure were treated with a partial beta-1-agonist prenalterol for 9." | ( Jespersen, C; Lyngborg, K; Rehling, M; Tangø, M; Trap-Jensen, J, 1988) |
| "Reduced mortality rates in congestive heart failure with vasodilator therapy has not been demonstrated, and prediction of clinical response to therapy is difficult." | ( Sutton, FJ, 1986) |
| "Fifty patients with congestive heart failure received, by infusion, 15 ml/kg body weight water load, and systemic hemodynamic, renal function, and neurohumoral parameters values were measured before, 2 days, and 1 month after randomly allocating patients to prazosin or captopril therapy." | ( Bichet, D; Chatterjee, K; Kortas, C; Manzini, C; Mettauer, B; Rouleau, JL; Tremblay, G, 1986) |
| "A case of chronic congestive cardiac failure and peripheral vascular disease due to thromboembolism was treated with captopril." | ( Grant, PK; Reuben, SR; Singh, SP, 1986) |
| "Ten patients with advanced congestive heart failure were treated with an arginine vasopressin V1 antagonist during hemodynamic monitoring to determine the contribution of vasopressin to vasoconstriction in this disorder." | ( Creager, MA; Cutler, SS; Faxon, DP; Gavras, H; Kohlmann, O; Ryan, TJ, 1986) |
| "Ten elderly females with congestive heart failure treated with oral furosemide were given four doses of sulindac and naproxen every twelve hours after a control day in a double-blind cross-over fashion." | ( Beermann, B; Eriksson, LO; Kallner, M, 1986) |
| "A total of 18 patients with chronic congestive heart failure were examined using an acute pharmacological test (25-50 mg of captopril) and during 2-week course treatment." | ( Agababian, IR; Akhmed, Kh; Ataullakhanova, DM; Mareev, VIu; Sazonova, LN, 1986) |
| "To determine whether congestive heart failure was the reason for these abnormalities, we then studied six additional patients before and after treatment of heart failure." | ( Crabb, JE; Dark, DS; Dunn, MI; Glatter, TR; Gollub, SB; Kerby, GR; Pingleton, SK, 1987) |
| "To impact on the development of clinical congestive heart failure as a complication of doxorubicin therapy, left ventricular ejection fraction was monitored with serial resting radionuclide angiocardiography in 1,487 patients with cancer over a seven-year period in both university and community hospital environments." | ( Alexander, J; Berger, HJ; D'Souza, A; Manatunga, A; McKenzie, WB; Sager, P; Schwartz, PE; Schwartz, RG; Setaro, J; Surkin, L, 1987) |
| "In conclusion, in patients with chronic cardiac failure, treatment with a calcium channel blocker produced sustained haemodynamic improvement, particularly on exercise, and combination with nitrate produced further benefit." | ( Hutton, I; Martin, W; McGhie, AI; Tweddel, AC, 1987) |
| "Twenty patients with congestive heart failure underwent hemodynamic studies before and over 10 hours after the administration of 25, 50, and 75 mg of indoramin, an alpha 1-adrenergic antagonist." | ( Binkley, PF; Leier, CV; Majetich, N; Uverferth, DV, 1987) |
| "Two patients with refractory congestive heart failure were treated with dobutamine for forty-eight to seventy-two hours with close monitoring of weight and symptomatology." | ( Margolis, J; Puram, B; Puram, V, 1987) |
| "In 14 patients with severe congestive heart failure, left ventricular pressure (measured by tip manometer) and derived variables were measured before and every 10 minutes after administration of oral milrinone (10 mg) for 50 minutes along with measurements of coronary sinus blood flow and drug plasma levels." | ( Jaski, BE; Piscione, F; Serruys, PW; Wenting, GJ, 1987) |
| "50 patients with congestive heart failure underwent monitored long-term treatment aimed at evaluating the effect of ibopamine (SB-7505), the 3,4-diisobutyryl ester of N-methyldopamine, on their condition." | ( Avanzini, Z; Bellogini, GC; Brusoni, B; Ciampani, N; Dei Cas, L; Gazzola, U; Maggi, GC; Mangiavacchi, M; Metra, M; Pinca, L, 1986) |
| "Seventeen non-digitalized congestive heart failure patients were treated with only the fixed-dose combinations of 20 mg furosemide and 50 mg spironolactone or 20 mg furosemide and 100 mg spironolactone, in a daily dose of 1 or 2 capsules, over a 4-week period." | ( Collia, LF; Ledesma, GA; Tutera, A; Yasky, J, 1986) |
| "Symptoms of cardiac failure were observed in a 60-year-old man 38 years after the therapy of cavernous tuberculosis of the right upper lobe with a paraffin oil plomb." | ( Bleese, N; Bleifeld, W; Erlemeier, HH; Klöppel, G; Kupper, W; Schreiber, C, 1986) |
| "Thirteen ambulatory patients with severe congestive heart failure were treated with weekly, outpatient 48-hour infusions of dobutamine." | ( Bates, ER; Dilworth, LR; Hodgson, JM; Kline, EM; Krell, MJ; Laufer, N; Pitt, B; Vogel, RA, 1986) |
| "Corvaton treatment of 23 patients with congestive heart failure caused by rheumatic valvular heart diseases, continued for 10 mos." | ( Koshlia, VI, 1986) |
| "In patients with congestive heart failure, 1 hour after administration of 4 mg of molsidomine there were significant reductions in systolic and diastolic pulmonary artery pressures of 25% and 30%, respectively." | ( Dirschinger, J; Rudolph, W, 1985) |
| "Twelve patients with Stage III cardiac failure of ischaemic (6 cases), myocardial (5 cases) or valvular (1 case) origin, were treated with oral amrinone." | ( Bounhoure, JP; Calazel, J; Massabuau, P; Miquel, JP; Puel, J, 1985) |
| "Lastly, in patients with congestive heart failure, with intravenous administration, resistance represents a pharmacodynamic phenomenon." | ( Brater, DC, 1985) |
| "6 fluid overloaded patients with congestive heart failure, NYHA classification IV, resistant to drug therapy, were treated by pump driven venovenous hemofiltration." | ( Glogar, DH; Kaindl, F; Silberbauer, K; Stummvoll, HK; Templ, H; Wittels, P, 1985) |
| "Long-term treatment of congestive heart failure with prazosin is disputed." | ( Bussmann, WD; Kaltenbach, M; Nadj, M; Reifart, N; Schmidt-Moritz, AD, 1985) |
| "Patients with severe congestive heart failure had a lower mean pretreatment APBT score (AR = 3." | ( Goldfarb, JP; LeJemtel, TH; Manzione, NC; Maskin, CS; Sternlieb, I, 1986) |
| "In 7 patients with congestive heart failure acute oral administration of ibopamine, a new dopamine derivative, induced a significant decrease in serum prolactin and aldosterone without affecting serum growth hormone or cortisol." | ( Barreca, T; Cantoni, V; Cicchetti, V; Franceschini, R; Gianrossi, R; Marchetti, G; Rolandi, E, 1986) |
| "Its potential role in the treatment of congestive heart failure was examined in short and long term oral studies." | ( Jewitt, DE; Timmis, AD, 1985) |
| "Eight patients suffering from congestive heart failure (NYHA III-IV) and pretreated with digoxin received muzolimine over 14 days in an open clinical study." | ( Ertl, G; Kahles, H; Kochsiek, K; Liebau, G; Riegger, G, 1985) |
| "Ten patients with congestive heart failure (CHF), in III and IV NYHA Class, were treated orally with a single dose of ibopamine ranging from 1." | ( Bianco, L; Brusoni, B; Col, J; Dei Cas, L; Ghirardi, P; Mangiavacchi, M; Metra, M, 1985) |
| "Although congestive heart failure has been reported with the combination of a beta blocker and either verapamil or nifedipine, it has not previously been reported for combination therapy that includes diltiazem." | ( Egan, T; McIntyre, KM; Parisi, AF; Strauss, WE, 1985) |
| "A patient with refractory congestive heart failure was treated, on an outpatient basis, with intermittent dobutamine using a totally implantable infusion pump." | ( Berger, M; McSherry, CK, 1985) |
| "Thus, milrinone therapy in congestive heart failure may be associated with the development of VPC complexity and with a significantly increased density of complex VPC forms." | ( Cody, RJ; Holmes, JR; Kligfield, P; Kubo, SH, 1985) |
| "30 patients with severe congestive heart failure (NYHA IV) unresponsive to medical management were treated by continuous hemofiltration (CHF)." | ( Glogar, DH; Kaindl, F; Silberbauer, K; Sochor, H; Stummvoll, HK; Wittels, P; Wolf, C, 1985) |
| "Eight hyponatraemic patients with severe congestive heart failure, long-term diuretic treatment, oedema, and increasing resistance to diuretic treatment, were studied with skeletal muscle biopsies and serum electrolytes before and after magnesium infusions." | ( Dyckner, T; Wester, PO, 1981) |
| "11 patients with congestive heart failure showed significant clinical and haemodynamic improvement after 4-week administration of 9 mg Prazosin/day." | ( Klein, W, 1982) |
| "Ten patients with severe chronic congestive heart failure (CHF) due to ischaemic heart disease treated with digitalis and diuretics were randomly allocated to oral treatment with prenalterol (100-200 mg daily in addition to their basal treatment) or to intensified treatment with diuretics in a cross-over trial." | ( Areskog, M; Dahlström, U; Karlsson, E; Wranne, B, 1984) |
| "Eleven of 12 patients with severe congestive heart failure who were pretreated with diuretics and digitalis benefited from long-term therapy with prazosin which was titrated to the individual's maximally tolerated dose." | ( Bertel, O; Bühler, FR; Burkart, F, 1982) |
| "Eight patients with severe congestive heart failure refractory to conventional therapy, including vasodilators, were given captopril (seven patients) or teprotide (one patient)." | ( Colucci, WS; Curfman, G; Dzau, VJ; Hollenberg, NK; Meggs, L; Williams, GH, 1980) |
| "Twenty patients with chronic congestive heart failure resistant to conventional treatment with digitalis, diuretics and vasodilators received captopril, an oral inhibitor of the angiotensin-converting enzyme, in daily doses of 200 mg and were followed up for 2 months or more." | ( Bounhoure, JP; Cassagneau, B; Fauvel, JM; Giraud, P; Kayanakis, JG; Puel, J; Sabot, G, 1981) |
| "2 Twelve patients with chronic congestive heart failure were conventionally treated with digitalis and diuretic therapy plus oral captopril (75-150 mg/day), and 14 patients were used as a control group." | ( Baraldi, P; Mattioli, G; Ricci, S; Teglio, V; Zaniol, P, 1982) |
| "Its recent use in treatment of congestive heart failure has shown prazosin to be comparable with nitroprusside in producing balanced arterial and venous dilation with generally sustained haemodynamic and clinical effects during long term therapy." | ( Brogden, RN; Kellerman, D; Romankiewicz, JA; Stanaszek, WF, 1983) |
| "In patients with congestive heart failure, 12 weeks of oral isosorbide dinitrate therapy improves resting and exercise hemodynamics, exercise capacity, and clinical status; tolerance develops to the systemic arterial vascular effects without attenuation of the venous and pulmonary vascular effects." | ( Huss, P; Leier, CV; Magorien, RD; Unverferth, DV, 1983) |
| "Fifty patients in severe congestive heart failure (CHF) were treated with captopril (Capoten; Squibb), an oral angiotensin-converting enzyme inhibitor, over a 2-year period (range 3-24 months, mean 8,6 +/- 7,7 months)." | ( Allman, B; Barlow, JB; Goldman, AP; Jardine, R; King, J; Pocock, WA; Steingo, L, 1983) |
| "In 20 patients with severe congestive heart failure (CHF), we studied the effects of the beta-adrenergic agonist pirbuterol compared to placebo in both an acute double-blind randomized trial and after long-term treatment." | ( Beller, GA; Bishop, HL; Carabello, BA; Gheorghiade, M; Grunwald, AM; Olukotun, AY; Pamelia, FX; Sirowatka, J; Taylor, CR; Watson, DD, 1983) |
| "Patients with symptoms of cardiac failure at rest or during light physical activity, X-ray signs of pulmonary congestion, proven need of digoxin therapy following earlier withdrawal, atrial fibrillation with a ventricular rate greater than 95 beats/min and patients in whom digitalis intoxication was suspected were excluded from the study." | ( Boman, K, 1983) |
| "In series 1 during acute cardiac failure, indomethacin administration produced striking reductions in RHF but failed to alter the high level of plasma renin activity (PRA)." | ( Davis, JO; Dietz, JR; Echtenkamp, SF; Freeman, RH; Villarreal, D, 1983) |
| "Therapy to decrease the load in congestive heart failure is now classified as acute and chronic vasodilator therapy." | ( Kawai, C; Nakajima, H; Sakurai, T; Yui, Y, 1984) |
| "Eighteen patients with congestive heart failure were studied in a double-blind, randomized, placebo-controlled withdrawal trial to evaluate the effectiveness of chronic oral amrinone therapy when added to conventional heart failure therapy." | ( Bashore, TM; Evans, JR; Huss, P; Leier, CV; Pacht, K; Unverferth, DV, 1984) |
| "Episodes of worsened congestive heart failure severe enough to mandate termination of double-blind treatment were as frequent in patients taking placebo (4[18%] of 21) as in those taking amrinone (4[13%] of 31; p = NS)." | ( Benotti, JR; DiBianco, R; Leier, CV; Shabetai, R; Silverman, BD, 1984) |
| "Seven patients with severe congestive heart failure (CHF) were treated with oral amrinone for a mean duration of 39 weeks (range 16 to 72)." | ( Forman, R; Frishman, W; LeJemtel, TH; Maskin, C; Ribner, H; Siegel, LA; Sonnenblick, EH; Strom, J; Wexler, J, 1983) |
| "Severe congestive cardiac failure developed in a few weeks in a 44 year old man who had undergone porto-caval anastamosis for post-hepatitis cirrhosis one year previously and then treated for anaemia by repeated blood transfusion and chronic daily oral iron therapy." | ( Azancot, I; Baudouy, P; Lombrail, P; Martin, E; Piekarski, A; Slama, R, 1983) |
| "No patient had congestive heart failure during therapy, but three patients had congestive heart failure two to four months after receiving 540, 525, and 530 mg/m2 of doxorubicin." | ( Dell, I; Hrushesky, WJ; Mukai, K; Steiner, B; Vukelich, M, 1984) |
| "296 patients with congestive heart failure or arterial hypertension receiving long term diuretic therapy were studied by skeletal muscle biopsies to assess their magnesium status." | ( Dyckner, T; Wester, PO, 1984) |
| "Ten patients with moderate to severe congestive heart failure (CHF) underwent central and regional hemodynamic measurements at rest and central hemodynamic measurements during exercise before and after the oral administration of nifedipine (0." | ( Hermiller, J; Huss, P; Leier, CV; Magorien, RD; Pacht, KD; Patrick, TJ; Unverferth, DV, 1984) |
| "No patient developed congestive heart failure (CHF) during therapy." | ( Hrushesky, WJ; Vukelich, M, 1984) |
| "Although therapy of congestive heart failure has to remain symptomatic in many cases, diagnostic evaluation should always precede initiation of therapy." | ( Baur, HR, 1984) |
| "In 6 patients with severe left-sided cardiac failure the absorption of drug from digoxin tablets was assessed by simultaneous administration of a commercially available tablet and of an intravenous tracer dose before and during therapy." | ( Benet, LZ; Benowitz, NL; Meister, W, 1984) |
| "The medical treatment prescribed in congestive heart failure also leads to changes in the handling of electrolytes." | ( Dyckner, T; Wester, PO, 1984) |
| "Ten patients suffering from refractory congestive heart failure were treated orally with Ibopamine 100 mg." | ( Forattini, C; Gabellini, A; Reffo, GC; Turrin, M, 1984) |
| "Volume overload congestive heart failure in dogs is associated with a reduced myocardial inotropic responsiveness to the exogenous administration of beta-adrenergic agonists [10, 11]." | ( Frankis, MB; Grossman, SJ; Newman, WH; Webb, JG, 1984) |
| "Ten patients with refractory congestive heart failure (CHF) were followed serially for systemic hemodynamic (radionuclide techniques) and M-mode echocardiographic changes during long-term captopril therapy with optimum doses." | ( Fouad, FM; Nakashima, Y; Tarazi, RC, 1982) |
| "Vasodilator treatment of congestive heart failure has provided an important new role for long-acting nitrates." | ( Abrams, J, 1980) |
| "This study delineates the effects of congestive heart failure on routine pulmonary function tests and assesses the changes in pulmonary function as congestive heart failure was treated." | ( George, RB; Light, RW, 1983) |
| "Seven patients with congestive heart failure receiving long-term diuretic treatment (more than three years) experienced idionodal tachycardia in the presence of apparently normal serum digoxin levels." | ( Cohen, L; Kitzes, R, 1983) |
| "In patients with acute and chronic congestive heart failure, single-dose administration of nifedipine was seen to lead to a decrease in systemic vascular resistance, left ventricular filling pressure and ventricular volumes as well as to an increase in stroke volume, ejection fraction and mean velocity of circumferential fiber shortening." | ( Camerini, F; Klugmann, S; Salvi, A, 1983) |
| "A 2-month-old female infant with congestive heart failure secondary to hepatic hemangiomatosis was treated with prednisone for five weeks without clinical improvement." | ( Fraser, JJ; Luckstead, EF; Smith, EI; Vorse, HB, 1983) |
| "Seven patients with severe chronic congestive heart failure were treated with a new cardiotonic agent, WIN 47203 (an analog of amrinone), for an average of 7." | ( Chadwick, B; Forman, R; Le Jemtel, TH; Maskin, CS; Sinoway, LS; Sonnenblick, EH, 1983) |
| "Chronic congestive heart failure patients being treated with the loop-blocking diuretic, furosemide, were found to have significantly reduced lymphocyte magnesium (p less than 0." | ( Counihan, TB; Ryan, MF; Ryan, MP, 1981) |
| "A patient with severe cardiac failure due to idiopathic congestive cardiomyopathy resistant to conventional therapy, responded to amrinone, a new non-glycosidic non-catecholamine positive inotropic agent." | ( Barrett, PA; Chong, B; Lvoff, R; Robinson, PJ, 1981) |
| "Its role in the treatment of cardiac failure requires further study and warrants further investigation." | ( Gillies, A; Morgan, T; Myers, J, 1980) |
| "In the long-term therapy of congestive heart failure hydrochlorothiazide together with potassium-sparing amiloride is a pleasant and effective therapy for patients with normal renal function, but the risk of hypokalaemia must be kept in mind also when using this combination." | ( Huikko, M; Varjoranta, K; Viherkoski, M, 1981) |
| "Some of cases of congestive heart failure (CHF) are intractable or refractory and respond poorly to conventional treatment." | ( Fujita, K; Ikuno, Y; Inoue, E; Komatsu, H; Kotsumi, K; Maeda, K; Minamikawa, H; Oku, H; Oshiro, T; Sawada, M; Shiota, K; Takeuchi, K; Tanaka, C; Tanaka, N; Tanaka, Y; Tsukano, Y; Yoshimura, T, 1982) |
| "Six patients with severe congestive heart failure refractory to conventional therapy, including vasodilators, were treated with oral amrinone for a mean duration of 41 weeks (range 20 to 72 weeks)." | ( Forman, R; Klein, NA; LeJemtel, TH; Maskin, CS; Sonnenblick, EH, 1982) |
| "Twelve patients with congestive heart failure were monitored with invasive and noninvasive techniques to evaluate the effect of vasodilator treatment." | ( Forfang, K; Ihlen, H; Kjekshus, J; Storstein, O; Thaulow, E, 1982) |
| "Twelve patients with severe chronic congestive heart failure (CHF) (NYHA class III and IV) resistant to digitalis and diuretics were treated with the postsynaptic alpha-blocking agent prazosin (PZ) (3 to 20 mg/day)." | ( Bertel, O; Bühler, FR; Burkart, F, 1981) |
| "Thirteen patients with advanced congestive heart failure (CHF) were treated with prazosin." | ( Ball, RM; Feldman, RC; Harrison, DC; Jaillon, P; Kates, RE; Winchester, MA, 1981) |
| "In 10 patients with severe chronic congestive heart failure, changes in hemodynamic and cardiac performance at rest and during exercise were evaluated following short-term oral prazosin therapy." | ( Chatterjee, K; Parmley, WW; Ports, TA; Rubin, SA, 1981) |
| "These observations show that "acute cardiac failure in fundamentally normal hearts" can occur after severe trauma and that treatment is possible." | ( Langenstein, H; Wolff, G, 1981) |
| "Six patients with severe congestive heart failure were treated with nitroprusside intravenously." | ( Benzing, G; Dillon, TR; Janos, GG; Kaplan, S; Meyer, RA, 1980) |
| "Twelve patients with refractory chronic congestive heart failure (Class IV NYHA), related to idiopathic dilated cardiomyopathy (10 patients); previous myocardial infarction (one patient) and peripartum cardiomyopathy (one patient), received Terminalia Arjuna, an Indian medicinal plant, as bark extract (500 mg 8-hourly) or matching placebo for 2 weeks each, separated by 2 weeks washout period, in a double blind cross over design as an adjuvent to maximally tolerable conventional therapy (Phase I)." | ( Bharani, A; Bhargava, KD; Ganguly, A, 1995) |
| "Nineteen patients with mild to moderate congestive heart failure due to idiopathic dilated cardiomyopathy (NYHA Class II-III) were studied before and after 8-11 weeks of therapy." | ( Eschenhagen, T; Hanrath, P; Jakob, H; Mende, U; Patten, M; Schmitz, W; Scholz, H; Schulte am Esch, J; Sigmund, M; Steinfath, M, 1995) |
| "In moderate congestive heart failure pulmonary overhydration may be detected at chest X-ray even if therapy is optimized to keep the urinary output normal and to prevent weight gain and dependent edema formation." | ( Agostoni, P; Guazzi, M; Lauri, G; Marenzi, G; Perego, GB; Sganzerla, P, 1994) |
| "Twenty patients with chronic congestive heart failure resulting from idiopathic dilated cardiomyopathy were randomized to receive intravenous infusion of dobutamine (5 micrograms/kg body weight per min, n = 10) or oral administration of MS-857 (15 mg, n = 10)." | ( Iwase, M; Nagata, K; Sobue, T; Yokota, M, 1995) |
| "In patients with congestive heart failure on antiarrhythmic therapy, the SPAF trial has shown an increase in cardiac mortality and arrhythmic deaths." | ( Lévy, S, 1994) |
| "Converting enzyme inhibitor treatment of congestive heart failure slows progression to failure and reduces mortality rate." | ( Friedrich, J; Ingwall, JS; Liao, R; Nascimben, L; Pauletto, P; Pessina, AC, 1995) |
| "Most frequently, diuretic therapy in congestive heart failure has as its main objective ridding the lungs of water." | ( Reyes, AJ, 1993) |
| "The first reported case of congestive cardiac failure in a child with Addison's disease secondary to fludrocortisone therapy is presented." | ( Byrne, GC; Jones, TW; Willis, FR, 1994) |
| "After treatment of the cardiac failure with frusemide (up to 500 mg daily intravenously), nitrates and captopril (25 mg daily by mouth) the diagnosis was confirmed by transoesophageal echocardiography." | ( Borchard, F; Horstkotte, D; Kober, R; Königshausen, T; Krahwinkel, W; Strauer, BE; Winter, J, 1994) |
| "In patients with moderate congestive heart failure, pulmonary overhydration may be detected by chest roentgenography even if therapy is optimized to keep the urinary output normal and to prevent weight gain and dependent edema formation." | ( Agostoni, P; Guazzi, MD; Lauri, G; Marenzi, G; Perego, G; Schianni, M; Sganzerla, P, 1994) |
| "In patients with congestive heart failure the set point of fluid balance is altered in spite of oral furosemide therapy; supplemental intravenous furosemide does not shift the set point, at least not when combined with ACE inhibition." | ( Agostoni, P; Guazzi, MD; Lauri, G; Marenzi, G; Perego, G; Schianni, M; Sganzerla, P, 1994) |
| "Standard methods of congestive heart failure therapy were used in each patient, including bed rest, restriction of sodium, and drug therapy including digoxin." | ( Hwang, SC; Jeong, CS; Jones, DW; Ryu, HS; Sands, CD; Sohn, K, 1994) |
| "Nine horses with (naturally acquired) congestive heart failure were treated with 2." | ( Reef, VB; Reimer, JM; Sweeney, RW, 1993) |
| "Fifteen patients with congestive heart failure underwent beta-blocker therapy." | ( Akaishi, M; Anzai, T; Baba, A; Handa, S; Mitamura, H; Nishimura, H; Ogawa, S; Yoshikawa, T, 1996) |
| "To report a patient with exacerbation of congestive heart failure after administration of polyethylene glycol-electrolyte lavage solution (PEG-ELS)." | ( Gardner, SF; Granberry, MC; White, LM, 1995) |
| "In untreated congestive heart failure, aldosterone plasma concentrations are elevated in proportion to the severity of the disease and are further increased by the use of diuretic treatment." | ( Zannad, F, 1995) |
| "The treatment of congestive heart failure has seen considerable changes: while treatment with diuretics, digitalis glycosides and vasodilators has remained the mainstay of therapy, recently neurohumeral inhibition has been developed as an important principle: ACE-inhibitors have been shown to significantly improve quality of life and exercise performance and to substantially reduce mortality." | ( Just, H, 1996) |
| "A case of severe fetal congestive heart failure due to occlusion of the ductus arteriosus in a mother treated with indomethacin for polyhydramnios and premature contractions is described." | ( Achiron, R; Berant, M; Hegesh, J; Kidron, D; Lipitz, S; Rotstein, Z, 1996) |
| "Patients with congestive heart failure are predisposed to magnesium deficit for many reasons, including neurohormonal activation, poor gastrointestinal absorption, and drug therapy." | ( Adams, KF; Patterson, JH; Sueta, CA, 1995) |
| "At a final experiment, acute cardiac failure was induced by administration of propranolol." | ( Earle, NR; Glaeser, DH; Hartley, CJ; Lawrie, GM; Li, Z; Michael, LH; Soltero, ER, 1996) |
| "Most patients with cardiac failure continue to be treated by general physicians, who are less likely to use echocardiography (P < 0." | ( Al-Mohammad, A; Hillis, GS; Jennings, KP; Wood, M, 1996) |
| "Progression to severe cardiac failure was also less frequent in the treatment group." | ( Aliot, E, 1996) |
| "Chagasic patients with congestive heart failure are usually treated with digitalis and converting enzyme inhibitors." | ( Bellabarba, G; Bishop, W; Davila, DF; Donis, JH; Hernandez, L; Khoury, AM; Lemorvan, C; Torres, A, 1996) |
| "The goals of therapy for congestive heart failure (CHF) are to improve quality of life and to prolong it." | ( Sorrentino, MJ, 1997) |
| "Treatment of patients with congestive heart failure with the angiotensin-converting enzyme inhibitor, fosinopril, reduce the elevated plasma endothelin level to normal values." | ( Bie, P; Emmeluth, C; Galatius-Jensen, S; Haunsø, S; Kastrup, J; Wroblewski, H, 1996) |
| "The efficacy of ACE inhibitors in congestive heart failure (CHF) might be affected by the pathophysiological status present at the onset of treatment." | ( Devaux, B; Henry, JP; Macé, B; Mulder, P; Richard, V; Thibout, E; Thuillez, C; Wimart, MC, 1997) |
| "Despite advances in medical therapy of congestive heart failure (CHF), morbidity and mortality for this disorder remain high." | ( Bradley, TD, 1996) |
| "Mortality of patients with severe congestive heart failure (CHF) is still high despite combined treatment with angiotensin-converting enzyme (ACE) inhibitors, diuretics, and digitalis." | ( Brilla, CG; Rupp, H; Scheer, C; Schencking, M, 1997) |
| "Treatment of congestive heart failure includes." | ( Hess, OM; Kaufmann, P; Mandinov, L; Matter, C, 1997) |
| "26 patients with moderate to severe congestive heart failure (New York Heart Association grade II to IV) and background treatment with digoxin, diuretics, and angiotensin converting enzyme inhibitors, and with a left ventricular ejection fraction < 25%." | ( Buchholz-Varley, C; Kalman, J; Kukin, ML; Mannino, MM; Ocampo, O, 1997) |
| "End-stage congestive heart failure (CHF) is associated with a high mortality rate and is often refractory to standard medical treatment." | ( Cesario, D; Clark, J; Maisel, A, 1998) |
| "In rats with congestive heart failure, type 1 angiotensin II receptor antagonist treatment (losartan) decreases basal renal sympathetic nerve activity and improves arterial baroreflex regulation of renal sympathetic nerve activity." | ( DiBona, GF; Jones, SY; Sawin, LL, 1998) |
| "In patients with congestive heart failure (CHF) receiving therapy with angiotensin-converting enzyme (ACE) inhibition, institution of calcium channel antagonism with amlodipine provided favorable effects." | ( Clair, MJ; Dodd, MG; Houck, WV; Kribbs, SB; Krombach, RS; Merritt, WM; Mukherjee, R; Spinale, FG, 1998) |
| "Patients with congestive heart failure may also profit from URO treatment, as it increases stroke volume and PCWP." | ( Forssmann, WG; Meyer, M; Richter, R, 1998) |
| "The relative impact of prior congestive heart failure and postoperative factors, such as treatment with cyclosporine, remains to be determined." | ( Andreassen, AK; Gullestad, L; Holm, T; Kvernebo, K; Simonsen, S, 1998) |
| "In our country, patients with congestive heart failure who are treated chronically with digoxin are usually advised by their physicians to stop taking the medication two days a week." | ( Gnocchi, CA; Khoury, MC; Mazzocchi, O; Noel, ME; Risso, JA; Torn, A; Yaryour, C, 1998) |
| "In patients with clinically evident congestive heart failure or ischemic heart disease who are receiving hemodialysis, administration of epoetin to raise their hematocrit to 42 percent is not recommended." | ( Besarab, A; Bolton, WK; Browne, JK; Egrie, JC; Goodkin, DA; Nissenson, AR; Okamoto, DM; Schwab, SJ, 1998) |
| "Despite advances in medical therapy, congestive heart failure remains a major cause of death in the developed world." | ( Ashen, D; Beuckelmann, DJ; Dixon, J; Duc, J; Kääb, S; McKinnon, D; Näbauer, M; Steinbeck, G; Tomaselli, GF, 1998) |
| "Eight patients with congestive heart failure, NYHA classes I through IV, were treated for 6 months with enalapril (E) 20 mg/d, and another 8 with losartan (L) 50 mg/d." | ( Ambrosio, GB; Ceconi, C; Dalla Libera, L; Facchin, L; Leprotti, C; Serafini, F; Vescovo, G; Volterrani, M, 1998) |
| "One woman died of progressive cardiac failure, one recovered clinically but also developed recurrent breast cancer, while the third recovered after commencement of medical therapy." | ( Abraham, R; Basser, RL; Fox, RM; Green, MD; To, LB, 1999) |
| "Forty-eight patients with congestive heart failure were investigated: 30 patients with dilated cardiomyopathy participating in a placebo-controlled trial (15 on placebo, 15 on metoprolol), and 18 patients treated by metoprolol in an open protocol." | ( Andersson, B; Lomsky, M; Strömblad, SO; Waagstein, F, 1999) |
| "Subgroup analysis of 464 patients with congestive heart failure treated with ACE inhibitors revealed 221 patients (48%) on aspirin and 243 patients not on aspirin." | ( Battler, A; Behar, S; Boyko, V; Goldbourt, U; Gottlieb, S; Leor, J; Reicher-Reiss, H, 1999) |
| "The management of patients with congestive heart failure (CHF) can place a significant economic burden on managed care organizations, leading providers to seek treatments that are cost-effective." | ( Noe, LL; Pezzella, SM; Trotter, JP; Vreeland, MG, 1999) |
| "Patients with congestive heart failure may thus benefit from adjunctive treatment with coenzyme Q10." | ( Hansen, HH; Munkholm, H; Rasmussen, K, 1999) |
| "All affected patients who developed congestive heart failure following administration of TT had some evidence of cardiac dysfunction prior to transplantation." | ( Alidina, A; Anderson, B; Baer, MR; Bambach, B; Barcos, MP; Bernstein, SH; Czuczman, MS; Ford, LA; Lawrence, D; McCarthy, PL; Proulx, GM; Slack, JL; Spangenthal, E; Wetzler, M, 1999) |
| "Two weeks before dying of congestive heart failure, a juvenile black rhinoceros (Diceros bicornis minor) received a single low dose of doxorubicin as part of combination chemotherapy for acute lymphoblastic leukemia." | ( Paglia, DE; Radcliffe, RW, 2000) |
| "Coenzyme Q10 is commonly used to treat congestive heart failure on the basis of data from several unblinded, subjective studies." | ( Alexander, BS; Fisher, ML; Freudenberger, R; Gottlieb, SS; Khatta, M; Krichten, CM; Robinson, SW, 2000) |
| "Patients with congestive heart failure were studied after administration of 0 mg, 75 mg, and 300 mg aspirin for 14 days." | ( Davie, AP; Love, MP; McMurray, JJ, 2000) |
| "We report 2 patients with congestive heart failure and concomitant toxic serum digoxin levels in whom cholestyramine administration increased clearance of digoxin and decreased serum digoxin elimination half-lives." | ( Roberge, RJ; Sorensen, T, 2000) |
| "The treatment of congestive heart failure focuses on three steps: 1." | ( Just, H, 2000) |
| "The general principles of management of congestive heart failure encompass patient evaluation and confirmation of the diagnosis, consideration, and correction of underlying remediable causes and precipitating factors, pharmacological treatment, patient education and counseling, and planned follow-up, as summarized in recently published guidelines." | ( Sharpe, N, 1999) |
| "Patients with cardiac failure died less frequently in the group treated with RF-bic (7 out of 24, 29%) than in the group treated with RF-lac (12 out of 21, 57%, P = 0." | ( Barenbrock, M; de la Motte, S; Hausberg, M; Matzkies, F; Schaefer, RM, 2000) |
| "Treatment of decompensated congestive heart failure (CHF) has often been based on titration of drugs to relieve patient's symptoms, a case that could be made for attempting to also treat neurohormonal abnormalities." | ( Cheng, V; Clopton, P; Garcia, A; Gardetto, N; Kazanagra, R; Krishnaswamy, P; Lenert, L; Maisel, A, 2001) |
| "Tailored therapy of decompensated congestive heart failure with hemodynamic monitoring is controversial." | ( Cheng, V; Clopton, P; Garcia, A; Gardetto, N; Kazanegra, R; Krishnaswamy, P; Maisel, A, 2001) |
| "Three patients developed congestive heart failure after the completion of chemotherapy." | ( Ikeno, A; Ishikawa, T; Iuchi, K; Matsuda, T; Nakamura, S; Ohtake, S; Okumura, H; Takamatsu, H; Takeshima, M; Usuda, K; Yoshida, T, 2000) |
| "We conclude that congestive heart failure is a risk of treatment with doxorubicin for Wilms' tumor." | ( Breslow, NE; D'Angio, GJ; Green, DM; Grigoriev, YA; Nan, B; Norkool, PA; Takashima, JR, 2001) |
| "Thirty-one patients with congestive heart failure who underwent only a single thoracentesis after diuretic therapy served as controls." | ( Fernández, C; Hernández, L; Martín, C; Romero-Candeira, S; Sánchez-Paya, J, 2001) |
| "Thus, in congestive heart failure patients who are undergoing conventional drug treatment, chronic clonidine administration exerts marked sympathoinhibitory effects without adversely affecting cardiac functions and clinical state." | ( Bertinieri, G; Grassi, G; Mancia, G; Pierini, A; Seravalle, G; Turri, C, 2001) |
| "In 2001, patients with decompensated congestive heart failure can be treated with various intravenous inotropic agents, vasodilator agents, invasive hemodynamic monitoring, ventricular assist devices, and cardiac transplantation." | ( Loh, E, 2001) |
| "Given a patient in fast AF and cardiac failure, 55% would treat with digoxin." | ( Ansari, M; Lip, GY; Williams, E, 2001) |
| "The rats with congestive heart failure were treated with FR139317 at two doses (1 and 5 mg ." | ( Chen, XC; Fang, C; Liu, YM; Luo, NS; Wu, W; Zhang, XM, 2001) |
| "Sixteen stable congestive heart failure patients, who had never been treated with ACE inhibitors, participated in the study." | ( Bizet-Nafeh, C; Costentin, A; Cribier, A; Derumeaux, G; Iacob, M; Joannides, R; Thuillez, C, 2001) |
| "METHODS - Eleven cardiac failure patients with marked ventricular dysfunction receiving treatment at a doctors office between 1994 and 1999 were studied." | ( Barretto, AC, 2001) |
| "Treatment of congestive heart failure has changed dramatically during the past 20 years, but diuretic drugs remain an essential component." | ( Ellison, DH, 2001) |
| "In patients with chronic congestive heart failure (CHF), aldosterone production may occur despite the administration of angiotensin-converting enzyme (ACE) inhibitors." | ( Caruso, B; Cicoira, M; Franceschini, L; Golia, G; Rossi, A; Zanolla, L; Zardini, P; Zeni, P, 2002) |
| "Beta-receptor downregulation due to congestive heart failure has an impact on the postoperative course in children with congenital disease and depends on heart failure therapy." | ( Buchhorn, R; Fielitz, J; Hetzer, R; Hulpke-Wette, M; Pregla, R; Regitz-Zagrosek, V; Ruschewski, W, 2002) |
| "Twelve patients with congestive heart failure treated with an ACE inhibitor were studied on two occasions, after abstaining from aspirin for 14 days, and after 14 days of aspirin 150 mg once daily." | ( Davie, AP; McMurray, JJ, 2002) |
| "In patients with congestive heart failure on standard therapy, including ACE inhibitors, BG9719 increased both urine output and GFR." | ( Abraham, WT; Beckman, E; Bennett, D; Bourge, R; Brater, DC; Dyer, F; Goldman, S; Gomez, M; Gottlieb, SS; Havranek, E; Thomas, I; Ticho, B, 2002) |
| "In 463 congestive heart failure (CHF) patients enrolled in the Danish Investigations Of Arrhythmia and Mortality On Dofetilide-CHF (DIAMOND-CHF) study, both pre-treatment and on-treatment day 2-6 QT dispersion was available from standard 12-lead ECGs." | ( Brendorp, B; Elming, H; Jun, L; Køber, L; Torp-Pedersen, C, 2002) |
| "In patients with congestive heart failure (CHF) receiving ACE inhibitors, acute administration of selective endothelin (ET) antagonists additionally improves systemic and cardiac hemodynamics." | ( Boujedaini, H; Henry, JP; Mulder, P; Münter, K; Renet, S; Richard, V; Thuillez, C, 2002) |
| "Since chagasic patients with severe congestive heart failure have left ventricular systolic dysfunction and neurohormonal activation, we administered metoprolol to nine chagasic patients who were in severe congestive heart failure." | ( Angel, F; Arata de Bellabarba, G; Dávila, DF; Donis, JH, 2002) |
| "Chronic pharmacotherapy of congestive heart failure deals with its special pathophysiology and acts on different sites of the cardiorenal axis." | ( Dominiak, P, 2002) |
| "In summary, beta blocker therapy of congestive heart failure has been established as an integral part in the combination therapy of patients with all clinical stages of heart failure." | ( Beuckelmann, DJ, 2002) |
| "No patients experienced congestive heart failure (CHF) before treatment." | ( Butine, MD; Edan, G; Eisenman, S; Ghalie, RG; Gonsette, RE; Goodkin, DE; Hartung, HP; Laurent, M; Mauch, E, 2002) |
| "Treatment for congestive heart failure (CHF) is an important factor in rising health care costs especially in patients requiring repeated hospitalisations." | ( Falkenstein, P; Follath, F; Gutzwiller, F; Müller, K; Reitberger, U; Spannheimer, A, 2002) |
| "404 consecutive patients admitted with congestive heart failure as one of the diagnoses and previously treated with furosemide (frusemide) for at least three months." | ( Almoznino-Sarafian, D; Alon, I; Averbukh, Z; Chachashvily, S; Chen-Levy, Z; Cohen, N; Golik, A; Gorelik, O; Modai, D; Shteinshnaider, M; Zaidenstein, R, 2003) |
| "Renal failure, severe congestive heart failure, and high dose furosemide treatment (> 80 mg/day) were associated with hypermagnesaemia (p < 0." | ( Almoznino-Sarafian, D; Alon, I; Averbukh, Z; Chachashvily, S; Chen-Levy, Z; Cohen, N; Golik, A; Gorelik, O; Modai, D; Shteinshnaider, M; Zaidenstein, R, 2003) |
| "Despite advances in treatment, chronic congestive heart failure carries a poor prognosis and remains a leading cause of cardiovascular death." | ( Byrne, JA; Cave, AC; Grieve, DJ; Shah, AM, 2003) |
| "Ten patients with stable chronic congestive heart failure (ejection fraction < 40%) on chronic treatment with metoprolol CR/XL." | ( Andersson, B; Bollano, E; Hjalmarson, A; Täng, MS; Waagstein, F, 2003) |
| "Forty in-patients with congestive heart failure were selected and randomly divided into 4 groups, the three treated groups I, II and III treated with digoxin combined with 20 ml, 40 ml and 60 ml of SMI respectively, and the control group, 10 patients in each group." | ( Mao, JY; Wang, HH; Xu, WR, 2003) |
| "In cases involving congestive heart failure and structural heart disease complicated by a depressed left ventricular systolic function, atrial fibrillation is currently treated with antiarrhythmic drugs possessing low proarrhythmic activity that prolong refractory period (Class 3), and with the even safer mortality-reducing beta-receptor blockers." | ( Csanádi, Z; Fazekas, T; Varró, A, 2003) |
| "The study was made in 45 patients with congestive heart failure treated in the Department of Cardiology." | ( Jołda-Mydłowska, B; Salomon, P, 2003) |
| "40 patients with congestive heart failure (CHF) treated in the Department of Cardiology of Medical University in Wrocław participated in this study." | ( Halawa, B; Karolko, B; Salomon, P, 2003) |
| "Thirty-eight patients with refractory congestive heart failure (men 23 and women 15) were enrolled in this study and randomly divided into two groups, control group and treatment group." | ( Li, WM; Lu, L, 2003) |
| "TREATMENT OF CARDIAC FAILURE CONSISTS OF THREE PRINCIPAL METHODS OR A COMBINATION OF THEM: (a) rest, or reduction of overload; (b) diuretic therapy and sodium restriction, and (c) administration of digitalis." | ( SELZER, A, 1963) |
| "In patients with decompensated chronic congestive heart failure (CHF), intensive unloading therapy allows an acute decrease in ventricular filling pressures and improves long-term prognosis." | ( Cioffi, G; Opasich, C; Stefenelli, C; Tarantini, L, 2003) |
| "Treatment of congestive heart failure with conventional medication significantly decreased the concentrations of MLC-I (1." | ( Dohi, Y; Goto, T; Sato, K; Sugiura, T; Takase, H; Toriyama, T; Ueda, R, 2003) |
| "The conventional treatment for cardiac failure plus oral prednisolone failed to bring clinical and echocardiographical improvement until the addition of intravenous (i." | ( Chan, YK; Chow, LT; Li, EK; Ng, HK; Tam, LS, 2003) |
| "In patients with severe congestive heart failure, sinus rhythm, and left bundle-branch block despite optimal pharmacological treatment, left univentricular pacing is feasible and results in significant midterm benefit in exercise tolerance and left ventricular function." | ( Bertault-Valls, V; Blanc, JJ; Etienne, Y; Fatemi, M; Gilard, M; Pennec, PY, 2004) |
| "When edema and congestive heart failure occurred later, they recovered only after medical therapy (diuretics, afterload reduction) was titrated and the rosiglitazone was withdrawn." | ( Singh, N, 2004) |
| "Oxipurinol's potential for treatment of congestive heart failure is based on the possibility that xanthine oxidase inhibitors may improve myocardial work efficiency by sensitising cardiac muscle cells to calcium ions, which are a key determinant of cardiac muscle function." | ( , 2004) |
| "In conclusion, the risk of cardiac failure or severe abnormalities increases with adriamycin treatment, radiotherapy and time since treatment, even after a follow-up of 15 years or more." | ( Dahan, M; de Vathaire, F; Hartmann, O; Lebidois, J; Merlet, P; Pein, F; Sakiroglu, O; Shamsaldin, A; Sidi, D; Villain, E, 2004) |
| "She developed severe cardiac failure, which did not respond to classical treatment." | ( De Wijngaard, S; Diltoer, MW; Hubloue, I; Huyghens, LP; Lauwers, R; Troubleyn, J; Vercammen, MJ, 2004) |
| "Seven episodes of congestive heart failure were observed during treatment in arm A." | ( Aldrighetti, D; Baldini, E; Bolognesi, A; Bruzzi, P; Carnino, F; Conte, PF; Gallo, L; Giannessi, P; Orlandini, C; Prochilo, T; Rosso, R; Salvadori, B; Venturini, M, 2004) |
| "We describe a young patient with congestive heart failure treated with doxorubicin (cumulative mean dose 420 mg/m2) in infancy because of pelvic sarcoma in whom the appearance of symptoms was related to pulmonary embolism." | ( Calabrò, R; Iacono, C; Iarussi, D; Indolfi, P; Martino, V; Muto, R, 2004) |
| "Activation of the neuroendocrine axis in congestive heart failure is of prognostic significance, and neurohumoral blocking therapy prolongs survival." | ( Doi, K; Francis, GS; Fukamachi, K; Hail, MD; Hoercher, KJ; McCarthy, PM; Ootaki, Y; Schenk, S; Starling, RC; Young, JB, 2004) |
| "Abnormal HRT caused by chronic congestive heart failure can be restored by beta-blocker therapy." | ( Chan, HL; Du, CC; Hwang, JJ; Lai, LP; Lin, JL; Lin, LY; Tseng, YZ, 2004) |
| "We describe a young patient with congestive heart failure treated with doxorubicin (cumulative mean dose 420 mg/m2) in infancy because of pelvic sarcoma in whom the appearance of symptoms was related to pulmonary embolism." | ( Calabrò, R; Iacono, C; Iarussi, D; Indolfi, P; Martino, V; Muto, R, 2004) |
| "There were studied 30 patients with congestive heart failure, III-IV functional NYHA class, that were not under ACEI or ARB's treatment." | ( Bodizs, G; Cebanu, M; Grosz, CS; Pop, D; Rusu, R; Zdrenghea, D, 2003) |
| "The incidence of congestive cardiac failure was similar with pioglitazone (12/1857) and non-pioglitazone (10/1856) treatments." | ( Belcher, G; Edwards, G; Goh, KL; Lambert, C; Valbuena, M, 2004) |
| "Digoxin has been used to treat congestive heart failure (CHF) for more than two centuries." | ( Song, S; Wang, L, 2005) |
| "Digoxin is used to treat congestive heart failure and atrial fibrillation." | ( Aomar Millán, I; Carrillo Santos, JC; Puche Cañas, E, 2004) |
| "Current pharmacological treatment of congestive heart failure (CHF) addresses changes in neurohumoral stimulation or cardiac responsiveness to such stimulation." | ( Andressen, KW; Birkeland, JA; Brattelid, T; Kaumann, AJ; Krobert, KA; Levy, FO; Osnes, JB; Qvigstad, E; Sejersted, OM; Sjaastad, I; Skomedal, T, 2005) |
| "Chronic treatment of animals with congestive heart failure with ABT-627 did not influence daily sodium excretion, whereas treatment with A192621 significantly improved daily sodium excretion." | ( Abassi, Z; Francis, B; Hoffman, A; Karram, T; Winaver, J, 2004) |
| "Despite the advances of the treatment of congestive heart failure, nearly half of the patients diagnosed with this disease five years ago are alive today." | ( Fügedi, K, 2005) |
| "In patients with symptomatic congestive heart failure receiving optimal therapy with an angiotensin-converting enzyme (ACE) inhibitor and a beta-blocker, the impact of using an angiotensin receptor blocker on submaximal exercise capacity and on neurohumoral activation at rest and during stress has not been investigated." | ( Blanchet, M; Curnier, D; De Champlain, J; Ducharme, A; Lamoureux, MC; Racine, N; Sheppard, R; Sirois, P; Tardif, JC; White, M, 2005) |
| "The use of ARAs for the treatment of myocardial failure and selected cases of hypertension, in combination with the current therapy, has been strongly supported by trials such as the Randomized Aldactone Evaluation Study (RALES) and the Eplerenone Neurohormonal Efficacy and Survival Study (EPHESUS)." | ( Magni, P; Motta, M, 2005) |
| "Recently, patients with severe cardiac failure and anaemia have also been shown to benefit from this treatment." | ( Slotki, I, 2005) |
| "Patients with congestive heart failure (CHF) suffer considerable morbidity and mortality despite advances in therapy." | ( Abashidze, A; Deutsch, V; George, J; Goldstein, E; Hamed, S; Keren, G; Miller, H; Roth, A; Shmilovich, H; Wexler, D, 2005) |
| "Conventional pharmacologic therapy for congestive heart failure, such as diuretics, digoxin, angiotensin-converting enzyme inhibitors, angiotensin-receptor blockers, and beta-adrenergic blockers, are routinely used and are quite effective." | ( Baldisseri, MR; Murali, S, 2005) |
| "Totally 203 patients with congestive heart failure were randomized into Group A (receiving benazepril 20 mg/day), Group B (benazepril,10 mg/day plus valsartan, 80 mg/day), and group C (valsartan 160 mg/day) for different treatment protocols on the basis of routine therapy for heart failure with digitalis, diuretics and beta blockers." | ( Liu, DS; Ye, JF, 2005) |
| "Severe decompensated congestive heart failure unresponsive to conventional diuretic and vasodilator treatment is a clinical challenge." | ( Perrier, A; Stampfli, T, 2006) |
| "In patients with congestive heart failure (CHF), continuous diuretic therapy may result in acute renal insufficiency (ARI)." | ( Chou, SY; Reiser, IW; Sun, WY, 2006) |
| "The management of chronic cardiac failure, a salt-sensitive state, frequently includes administration of a loop diuretic to enhance urinary Na excretion." | ( Khouzam, RN; Klemis, JE; Mangold, TA; Nelson, MD; Wall, BM; Weber, KT, 2006) |
| "Many patients with congestive heart failure (CHF) fail to respond to maximal CHF therapy and progress to end stage CHF with many hospitalizations, poor quality of life (QoL), progressive chronic kidney disease (CKD) which can lead to end stage kidney disease (ESKD), or die of cardiovascular complications within a short time." | ( Iaina, A; Schwartz, D; Silverberg, DS; Steinbruch, S; Wexler, D; Wollman, Y, 2006) |
| "Decompensation in patients with congestive heart failure remains a treatment problem." | ( Yancy, CW, 2006) |
| "Treatment of congestive heart failure aims to improve left ventricular function by reducing the pressure and volume overload." | ( Al-Meslmani, BM; Fahoum, SK; Shamia, MG, 2007) |
| "Forty-four patients with chronic congestive heart failure were enrolled in the study to randomly receive carvedilol or bisoprolol in addition to background therapy." | ( Hua, C; Hua, L; Huang, J; Huang, Y; Jiang, W; Li, F; Li, N; Li, Y; Wang, F; Wu, Y; Xu, Z, 2007) |
| "The ESCAPE trial (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) was a randomized, controlled study designed to evaluate the utility of a pulmonary artery catheter plus clinical assessment vs clinical assessment alone in guiding therapy in patients hospitalized with New York Heart Association class IV HF due to systolic dysfunction (left ventricular ejection fraction <30%)." | ( Butler, J; Cotts, W; DeMarco, T; DiSalvo, TG; Fonarow, GC; Francis, GS; Gheorghiade, M; Hare, JM; Hellkamp, AS; O'Connor, CM; Pauly, DF; Piña, IL; Rogers, J; Rossi, JS; Shin, DD; Stough, WG, 2007) |
| "Rapid diagnosis of congestive heart failure (CHF) is essential to treatment." | ( Becerra, S; Brown, CA; Hvingelby, EM; Kam, K; Schuster, L; Schuster, R; Stewart, D; Waxman, K, 2007) |
| "As clinicians' knowledge about congestive heart failure (CHF) improves, so does the ability to treat and monitor patients with this condition." | ( Erling, P; Mazzaferro, EM, 2008) |
| "A mainstay of therapy for congestive heart failure has been the use of potent diuretic agents, such as furosemide, that target the kidney to enhance sodium and water excretion." | ( Burnett, JC; Cataliotti, A; Chen, HH; Martin, FL, 2008) |
| "Our results suggest that, in congestive heart failure, ETB receptors are essential to limit circulating endothelin levels, which may argue for improved cardiac benefits after long-term treatment with highly selective ETA-receptor antagonists." | ( Bkaily, G; Carrier, E; D'Orleans-Juste, P; Fecteau, MH; Honoré, JC; Tirapelli, CR, 2008) |
| "We describe a case of severe congestive heart failure and right ventricular overload associated with overt hyperthyroidism, completely reversed with antithyroid therapy in a few week." | ( Di Giovambattista, R, 2008) |
| "Acute development of congestive cardiac failure associated with bortezomib therapy occurs very rarely or may be underestimated." | ( Gonullu, E; Hacihanefioglu, A; Tarkun, P, 2008) |
| "Treatment of chronic congestive heart failure resulted in a transient increase in UTII concentration except for patients with diastolic heart failure or diabetes." | ( Jołda-Mydłowska, B; Mazurek, W; Salomon, P, 2006) |
| "Patients with congestive heart failure (CHF) suffer considerable morbidity and mortality despite advances in therapy." | ( Carić, D; Carić, T; Derek, O, 2008) |
| "Hospitalized patients with congestive heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction (left ventricular ejection fraction < or =40%) treated with standard therapy were randomized 3 to 14 days after the acute myocardial infarction to additional treatment with eplerenone (25 to 50 mg/d; n=3319) or placebo (n=3313)." | ( Bakris, G; DiCarlo, L; Mukherjee, R; Pitt, B; Ruilope, LM, 2008) |
| "NYHA status of cardiac failure between starting treatment and the third questionnaire improved for 39." | ( Aurich-Barrera, B; Shakir, SA; Wilton, LV, 2009) |
| "He developed congestive heart failure 5 days after administration of cyclophosphamide." | ( Furukawa, Y; Hashimoto, H; Imai, Y; Katayama, M; Kurata, M; Morioka, S; Nagai, K; Tamita, K, 2009) |
| "After treatment of cardiac failure, N-terminal pro-brain natriuretic peptide levels decreased significantly (p < 0." | ( Colak, O; Kilic, Z; Sezgin Evim, M; Ucar, B, 2010) |
| "Difficulty in distinguishing congestive heart failure (HF) from other causes of dyspnoea in the emergency department (ED) may result in delay in appropriate treatment and referral." | ( Bais, R; Gould, I; Koe, L; Robaei, D; Stewart, T; Tofler, GH, 2011) |
| "A 73-year-old woman with severe congestive heart failure was treated by implantation with a sirolimus-eluting stent (SES; Cypher Bx Velocity(®)) in the left main coronary artery (LMCA) using the staged T-stent, kissing balloon, and hugging balloon techniques." | ( Endo, A; Ishikawa, T; Kashiwagi, Y; Mutoh, M; Suzuki, T, 2011) |
| "Unlike the therapy of congestive heart failure, there was only a modest progress in the medical treatment for acutely decompensated heart failure over the past several decades." | ( Caglayan, E; Er, F; Erdmann, E; Gassanov, N, 2011) |
| "Clinical translation is mature in cardiac failure, knowledge of cardiac neural pathophysiology having led to the introduction of beta-adrenergic blockers, an effective therapy." | ( Esler, M; Parati, G, 2012) |
| "106 patients with congestive heart failure and LVEF ≤ 45% on optimal pharmacotherapy were included in the study." | ( Galkova, L; Ludka, O; Musil, V; Spinar, J; Trna, J, 2013) |
| "In humans with congestive heart failure (CHF), better outcome is correlated with lower natriuretic peptide (NP) levels after starting treatment and greater percentage reduction of NP levels." | ( Gerlach, N; Klima, A; Weber, K; Wess, G; Wolf, J, 2012) |
| "Novel treatment of congestive heart failure (HF) involves utilizing unique pathways to improve upon contemporary therapies." | ( Agarwal, R; Barnes, M; Benza, RL; Coons, J; Kanwar, M; Murali, S; Raina, A; Sokos, G, 2013) |
| "The cat subsequently developed congestive heart failure secondary to myocardial failure and was treated with pimobendan, enalapril, furosemide, calcitriol and calcium salts." | ( Lie, AR; MacDonald, KA, 2013) |
| "In patients with congestive heart failure (CHF), use of loop diuretic therapy may result in acute kidney insufficiency (AKI)." | ( Cangiano, JL; López, JE; Marmorato, R; Pagán, P; Ramírez, T; Ricci, F; Soto-Salgado, M; Vega, J, 2013) |
| "The patient was treated for congestive heart failure because of dilated cardiomyopathy with furosemide, enalapril, pimobendan and l-carnitine." | ( Delk, KW; Eshar, D; Garcia, E; Harkin, K, 2014) |
| "We stopped bortezomib and started acute congestive heart failure treatment." | ( Aota, Y; Gotoh, A; Hanyu, N; Honma, T; Kitagawa, N; Komatsu, N; Morisaki, M; Yokoyama, T, 2015) |
| "Treatment of congestive heart failure (CHF) with loop diuretics, such as furosemide, may be associated with complications, including worsening renal function and metabolic or electrolyte disturbances." | ( Akashi, YJ; Kida, K; Kimura, K; Matsumoto, N; Miyake, F; Shibagaki, Y; Tominaga, N, 2015) |
| "The case of a neonate with congestive heart failure complicated with chylothorax after palliative surgery for transposition of the great arteries treated with tolvaptan is reported." | ( Inukai, S; Ito, K; Kato, T; Nagasaki, R; Saitoh, S; Sato, N; Sugiura, T; Suzuki, K, 2015) |
| "We herein report a case of congestive heart failure which developed during osimertinib treatment." | ( Ichihara, E; Kano, H; Kiura, K; Ninomiya, K; Tanimoto, M; Watanabe, H, 2017) |
| "Adults with SIADH or congestive heart failure (CHF) treated with tolvaptan for a serum sodium concentration ≤ 130 mEq/L at 5 US hospitals." | ( Bhasin, B; Bohm, NM; Crawford, R; Kelley, D; Morris, JH; Nemecek, BD; Nietert, PJ; Velez, JCQ, 2018) |
| "Adverse events associated with cardiac failure were compared between treatment arms in each study separately." | ( Kim, EE; Polli, A; Usari, T; Wilner, KD, 2019) |
| "We herein report two cases of congestive heart failure in patients treated with carfilzomib." | ( Ikoma, T; Maekawa, Y; Nagata, Y; Naruse, Y; Ohtani, H; Ono, T; Sano, M; Saotome, M; Suwa, K; Urushida, T, 2019) |
| "Recently, some RCTs in congestive heart failure (CHF) demonstrated that intravenous administration of ferric carboxymaltose improves patient symptoms and reduces incidence of hospitalization for worsening heart failure." | ( Hamano, T, 2019) |
| "Sustained AF, ischemic heart disease, congestive heart failure, hyperlipidemia, and female sex were the factors influencing cognitive performance after 1-year treatment with DOAC in patients with AF and previous ischemic stroke." | ( Bonetti, B; Bovi, P; Bovi, T; Cappellari, M; Forlivesi, S; Micheletti, N; Musso, AM; Sajeva, G; Tomelleri, G; Valbusa, V; Zucchella, C, 2021) |
| "Although chemotherapy-induced congestive heart failure (CHF) is a well-known adverse event in cancer survivors, the long-term risk of standard low-dose anthracycline has not yet been reported." | ( Ahn, SH; Chung, IY; Han, W; Lee, JW; Moon, HG; Noh, DY; Shin, KH; Son, BH, 2020) |
| "We often encounter patients with congestive heart failure refractory to conventional diuretics therapy, and Kampo Goreisan is receiving great concern to mediate body water balance particularly for such a cohort." | ( Imamura, T; Kakeshita, K; Kinugawa, K; Onoda, H, 2023) |
| "The safety signal for developing cardiac failure for both the drugs did not differ between patients with and without concomitantly administered medications." | ( Endo, M; Fujiwara, M; Goto, M; Shimizu, T; Uchida, M, 2023) |
| "Hypertension, cardiac failure, coronary artery stenosis, and myocardial infarction could potentially result in serious outcomes and some cases occurred earlier or even more than 1 year after starting administration." | ( Kanbayashi, Y; Nakano, K; Shimizu, T; Uchida, M; Wakabayashi, H, 2023) |
| "The role of taurine in the treatment of congestive heart failure (CHF) in dogs without systemic deficiency is unexplored." | ( Adin, D; Brethel, S; Girens, R; Locker, S; Meurs, K; Rivera, P, 2023) |
| "Furosemide is a mainstay of treatment in congestive heart failure (CHF) and is widely prescribed to dogs and cats by several formulations, including the subcutaneous one." | ( Aspidi, F; Mazzoldi, C; Romito, G, 2023) |